<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003730.pub2" GROUP_ID="SCHIZ" ID="888002051309570416" MERGED_FROM="" MODIFIED="2013-01-31 21:07:35 +0000" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Kristian's contacts to be added&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-04-24 19:20:08 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="7564" REVMAN_SUB_VERSION="5.0.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2013-01-31 21:07:35 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Glutamatergic drugs for schizophrenia</TITLE>
<CONTACT MODIFIED="2013-01-31 21:07:35 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="16295" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Kristian</FIRST_NAME><LAST_NAME>Wahlbeck</LAST_NAME><POSITION>Professor of Psychiatry</POSITION><EMAIL_1>kristian.wahlbeck@thl.fi</EMAIL_1><EMAIL_2>kristian.wahlbeck@helsinki.fi</EMAIL_2><URL>http://www.ithaca-study.eu/more_research.html</URL><ADDRESS><DEPARTMENT>Department of Mental Health and Substance Abuse Services</DEPARTMENT><ORGANISATION>THL National Institute for Health and Welfare</ORGANISATION><ADDRESS_2>PO Box 220</ADDRESS_2><CITY>Helsinki</CITY><ZIP>FIN-00531</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 20 610 7300</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-01-31 21:07:35 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="118532E782E26AA201DC7B3E841F7BC8" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jari</FIRST_NAME><LAST_NAME>Tiihonen</LAST_NAME><POSITION>Professor and Chairman</POSITION><EMAIL_1>jari.tiihonen@niuva.fi</EMAIL_1><ADDRESS><DEPARTMENT>Department of Forensic Psychiatry</DEPARTMENT><ORGANISATION>University of Kuopia</ORGANISATION><ADDRESS_1>Niuvanniemi Hospital</ADDRESS_1><ADDRESS_2>P.O.Box 320</ADDRESS_2><CITY>Helsinki</CITY><ZIP>FIN-70240 kuopio</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 17 203 202</PHONE_1><FAX_1>+358 17 203 494</FAX_1></ADDRESS></PERSON><PERSON ID="16295" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Kristian</FIRST_NAME><LAST_NAME>Wahlbeck</LAST_NAME><POSITION>Professor of Psychiatry</POSITION><EMAIL_1>kristian.wahlbeck@thl.fi</EMAIL_1><EMAIL_2>kristian.wahlbeck@helsinki.fi</EMAIL_2><URL>http://www.ithaca-study.eu/more_research.html</URL><ADDRESS><DEPARTMENT>Department of Mental Health and Substance Abuse Services</DEPARTMENT><ORGANISATION>THL National Institute for Health and Welfare</ORGANISATION><ADDRESS_2>PO Box 220</ADDRESS_2><CITY>Helsinki</CITY><ZIP>FIN-00531</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 20 610 7300</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-04-24 19:19:35 +0100" MODIFIED_BY="Tessa Jane Grant" NOTES="&lt;p&gt;Minor update: 2/15/06&lt;/p&gt;" NOTES_MODIFIED="2008-04-24 19:19:35 +0100" NOTES_MODIFIED_BY="Tessa Jane Grant">
<UP_TO_DATE>
<DATE DAY="10" MONTH="2" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="2" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="2" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2013-01-31 21:07:35 +0000" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-31 21:07:35 +0000" MODIFIED_BY="Claire Irving"><DATE DAY="31" MONTH="1" YEAR="2013"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2013-01-31 21:07:35 +0000" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-31 21:07:35 +0000" MODIFIED_BY="Claire Irving"><DATE DAY="18" MONTH="1" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 21:11:24 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="13" MONTH="4" YEAR="2011"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-04-13 17:49:53 +0200" MODIFIED_BY="Claire Irving"><DATE DAY="11" MONTH="11" YEAR="2009"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 11:37:50 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="5" MONTH="8" YEAR="2009"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-05 14:24:04 +0200" MODIFIED_BY="Bethany York">
<DATE DAY="24" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="10" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Psychiatry, University of Helsinki</NAME>
<COUNTRY CODE="FI">Finland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>STAKES National Research and Development Centre for Welfare and Health</NAME>
<COUNTRY CODE="FI">Finland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Stockmann Foundation</NAME>
<COUNTRY CODE="FI">Finland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-04-24 19:20:08 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-04-24 19:20:08 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-24 19:20:08 +0100" MODIFIED_BY="[Empty name]">Glutamatergic drugs for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2008-04-24 19:19:55 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a severe psychiatric disease characterised by positive symptoms such as hallucinations and delusions and negative symptoms such as blunted affect and emotional withdrawal. People with schizophrenia may also suffer from cognitive deficits. Current medication is effective in reducing positive symptoms, but negative and cognitive symptoms are fairly resistant to treatment. Antipsychotic drugs act mainly on the dopamine system in the brain, although other neurotransmitter systems may also play a role in schizophrenia.</P>
<P>We sought to review all randomised trials that used glutamatergic drugs in the treatment of schizophrenia. This review shows that substances acting on the glutamate system may improve symptoms when added to regular antipsychotic medication, although the available evidence base is too limited to allow for any firm conclusions. Presently, glutamatergic drugs are not available for clinical use. Additional research is needed to determine their ultimate role in the treatment of schizophrenia.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>It has been shown that central nervous system dopamine can play a major role in the pathophysiology of schizophrenia. Brain glutamate is thought to mediate symptoms in schizophrenia due to the influence of glutamate neurons on the dopaminergic transmission in the brain. It might be possible to decrease negative symptoms and the cognitive impairment of people with schizophrenia by treatment with glutamatergic drugs.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy of glutamatergic drugs in the treatment of schizophrenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Schizophrenia Group's Trials Register (May 2002 and October 2003), inspected references of all identified studies and contacted relevant authors.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included all randomised controlled trials in which glutamatergic medication was administered to people with schizophrenia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We reliably selected studies, quality rated them and extracted data. For dichotomous data, we estimated relative risks (RR), with the 95% confidence intervals (CI). Where possible, we calculated the number needed to treat/harm statistic (NNT/H) and used intention-to-treat analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included eighteen short-term trials with 358 randomised participants. The single studies were small with numbers of participants ranging between six and 51. All trials were short-term trials with a maximum duration of 12 weeks. In all of these trials, glycine, D-serine, D-cycloserine, or ampakine CX516 was used to augment the effect of antipsychotic drugs. D-cycloserine, a partial agonist of NMDA receptors' glycine site, seemed ineffective towards the symptoms of schizophrenia. NMDA receptor co-agonists glycine and D-serine showed some effects in reducing the negative symptoms of schizophrenia (n=132, SMD -0.66, CI -1.0 to -0.3, p=0.0004), but the magnitude of the effect was moderate. Furthermore, when responder rates rather than mean scores of negative symptoms were analysed the data were inconsistent: There was no difference in responder rates between glycine and the control in terms of more than 20% improvement of negative symptoms (n=62, RR 0.70, CI 0.3 to 1.71) and only a borderline significant superiority in terms of more than 50% improvement (n=62, RR 0.87, CI 0.8 to 1.00). There were also some effects in favour of glycine and/or D-serine in terms of overall and general symptoms, but the results were again inconsistent and depended on the response definition applied. Available rating scale data on positive symptoms and cognitive functioning did not indicate a statistically significant effect of glycine or D-serine.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>In general, all glutamatergic drugs appeared to be ineffective in further reducing positive symptoms of the disease when added to the existing antipsychotic treatment. Glycine and D-serine may somewhat improve negative symptoms when added to regular antipsychotic medication, but the results were not fully consistent and data are too few to allow any firm conclusions. Many participants in the included trials were treatment-resistant which may have reduced treatment response. Additional research on glutamatergic mechanisms of schizophrenia is needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>People with schizophrenia have received treatment with conventional antipsychotic drugs (dopamine D2 receptor antagonists) since the 1950's and, more recently, with atypical antipsychotics (mainly D2 and 5HT2 receptor antagonists). Although conventional antipsychotics are effective against positive symptoms, such as hallucinations and delusions, they are ineffective against the negative symptoms (<LINK REF="REF-Kirkpatrick-2001" TYPE="REFERENCE">Kirkpatrick 2001</LINK>) and cognitive deficits (<LINK REF="REF-Javitt-1999" TYPE="REFERENCE">Javitt 1999</LINK>) of the disease. Some new atypical antipsychotics may be more effective in reducing negative symptoms (<LINK REF="REF-Borison-1995" TYPE="REFERENCE">Borison 1995</LINK>, <LINK REF="REF-Leucht-1999" TYPE="REFERENCE">Leucht 1999</LINK>) and cognitive deficits (<LINK REF="REF-Harvey-2001" TYPE="REFERENCE">Harvey 2001</LINK>). However, the mechanism of action of this broader therapeutic effect for treating schizophrenia is not clear. For example, the effects of the atypical antipsychotic clozapine on negative symptoms and cognitive deficits are thought to be linked to NMDA (N-methyl-D-aspartate) glutamate receptor action. The effects of antipsychotics on negative and cognitive symptoms may be mediated by glutamate, since in some clinical trials glutamatergic medication has been shown to be effective in improving negative and cognitive symptoms (<LINK REF="REF-Tsai-2002" TYPE="REFERENCE">Tsai 2002</LINK>).</P>
<P>Technical background of glutamatergic drugs</P>
<P>Dopamine-glutamate interactions<BR/>The dopamine hypothesis remains the leading theory on pathophysiology of schizophrenia, but new evidence shows that other monoamines as well as glutamate and gamma-aminobutyric acid (GABA) are also of interest. Glutamatergic neurons influence dopaminergic neurotransmission in a complex way. Evidence from clinical trials, in which glutamate antagonists (such as PCP [phencyclidine, 'angel dust'], MK-801 or ketamine) provoke schizophrenia-like symptoms, has changed schizophrenia research toward a multifactorial view. It is therefore proposed that glutamate agonists could reduce the symptoms of schizophrenia (<LINK REF="REF-Carlsson-2001" TYPE="REFERENCE">Carlsson 2001</LINK>).</P>
<P>Biochemical background<BR/>Glutamate is an excitatory amino acid neurotransmitter which is derived from glucose and glutamine (<LINK REF="REF-Kaplan-1998" TYPE="REFERENCE">Kaplan 1998</LINK>). Its predominant function is not as a neurotransmitter, but as a building block in protein synthesis and as a substance in nitrogen metabolism (<LINK REF="REF-Nelson-2000" TYPE="REFERENCE">Nelson 2000</LINK>). As a neurotransmitter, it acts on two main groups of glutamate receptors. There are ionotropic receptors (like NMDA, AMPA (alfa-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid), kainate receptors) and G-protein coupled metabotropic receptors. The NMDA receptors function together with the AMPA and kainate receptors, which are needed to activate NMDA receptors. Activation also requires a co-agonist glycine to be bound to its binding site on the NMDA receptor (glycine is used as glutamatergic substance, see Types of interventions) (<LINK REF="REF-Goff-2001b" TYPE="REFERENCE">Goff 2001b</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the efficacy of glutamatergic drugs in the treatment of schizophrenia.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We included all relevant randomised controlled trials. Pseudo-randomised trials were not included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people with schizophrenia or with a similar non-affective psychosis, diagnosed by any criteria.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The duration of treatment was at least two weeks.</P>
<P>1. All relevant glutamatergic drugs, given as sole treatment for schizophrenia, any dose, any means of administration. <BR/>2. All relevant glutamatergic drugs, given as an adjunctive to antipsychotic drugs, any dose, any means of administration. <BR/>3. Routine medication.<BR/>4. Placebo or no intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Death<BR/>1.1 Suicide<BR/>1.2 Natural causes</P>
<P>2. Leaving the study early </P>
<P>3. Global response<BR/>3.1 Relapse defined as hospitalisation or clinically significant worsening of disease<BR/>3.2 No clinically significant response in global state - as defined by each of the studies*<BR/>3.3 Average end score in global state</P>
<P>4. Mental state<BR/>4.1 No clinically significant response on psychotic symptoms - as defined by each of the studies<BR/>4.2 Average end score on psychotic symptoms<BR/>4.3 No clinically significant response on positive symptoms - as defined by each of the studies<BR/>4.4 Average end score in positive symptoms<BR/>4.5 No clinically significant response on negative symptoms - as defined by each of the studies*<BR/>4.6 Average end score in negative symptoms</P>
<P>5. Cognitive functions<BR/>5.1 No improvement in cognitive functions*<BR/>5.2 Average end score in cognitive functions</P>
<P>6. Adverse effects<BR/>6.1 General<BR/>6.2 Specific</P>
<P>7. Service utilisation outcomes<BR/>7.1 Hospital admission<BR/>7.2 Days in hospital</P>
<P>8. Economic outcomes</P>
<P>9. Quality of life/satisfaction with care for either recipients of care or carers<BR/>9.1 No significant improvement in quality of life/satisfaction - as defined by each of the studies<BR/>9.2 Average end score in quality of life/satisfaction</P>
<P>* = Primary outcomes of interest.<BR/>All outcomes were grouped as short-term (up to 12 weeks), medium-term (13 to 26 weeks) and long-term (more than 26 weeks).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>1. Electronic searching<BR/>We searched the Cochrane Schizophrenia Group's Register (May 2002 and updated in October 2003) using the phrase:</P>
<P>[glutamate* OR glutamine* OR glutamic* OR aspartate* OR glycine* OR NMDA* OR AMPA* OR kainate* OR d-serine* OR serine* OR cycloserine* OR SC 49088 OR (R)-4-amino-isoxazolidinone OR ampakine* OR CX 516 OR CAS 154235-83-3]</P>
<P>The Cochrane Schizophrenia Group undertakes searches of a number of databases, conference proceedings and extracted citations of all trials relating to schizophrenia or chronic/serious mental illnesses. Regular searches of Biological Abstracts CINAHL, the Cochrane Library, EMBASE, MEDLINE, RUSSMED, LILACS, PSYNDEX and PsycLIT are undertaken by the Trial Search Co-ordinator, and relevant citations are added to an in-house register.</P>
<P>2. Reference searching<BR/>We also inspected the reference lists of all identified studies (included and excluded) for further studies. </P>
<P>3. Personal contact<BR/>We contacted the first author of each included study for information regarding unpublished trials and extra data on the published trials.</P>
<P>4. Pharmaceutical industry<BR/>We contacted relevant drug companies in order to obtain additional information regarding clinical trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of trials<BR/>We (HT, KW) independently inspected the citations identified in the search outlined above. We identified potentially relevant abstracts and ordered full papers and reassessed these for inclusion and methodological quality. We discussed and reported any disagreement.</P>
<P>2. Assessment of quality<BR/>Again, working independently, we allocated trials to three quality categories as described in the Cochrane Reviewers' Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). When disputes arose as to which category a trial was allocated, again, we attempted resolution by discussion. When this was not possible, and further information was necessary, we did not enter data into the analyses but allocated the study to the list of those awaiting assessment. We only included trials in Category A or B in the review. A short description of the three categories is as follows:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>3. Data management<BR/>3.1 Data extraction<BR/>We (HT and KW) performed the data extraction, and where further clarification was needed we contacted the authors of trials to provide missing data.</P>
<P>3.2 Intention to treat analysis<BR/>We excluded data from studies where more than 50% of participants in any group were lost to follow up (this does not include the outcome of 'leaving the study early'). In studies with less than 50% dropout rate, we considered people leaving the study early to have had the negative outcome, except for the event of death.</P>
<P>3.3 Cross-over trials<BR/>Since some included trials were conducted with cross-over design we made a post-hoc decision to extract solely end-point data of the first segment in order to avoid any carry over effect (<LINK REF="REF-Sibbald-1998" TYPE="REFERENCE">Sibbald 1998</LINK>).</P>
<P>4. Data analysis<BR/>4.1 Binary data<BR/>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). We also calculated the number needed to treat statistic (NNT) when the result was statistically significant. If heterogeneity was found (see section 5) we used a random effects model. </P>
<P>4.2 Continuous data<BR/>4.2.1 Skewed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards are applied to all data before inclusion: (a) standard deviations and means were reported in the paper or were obtainable from the authors; (b) when a scale starts from a finite number (such as zero), the standard deviation, when multiplied by two, was less than the mean as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite start and end point and this rule can be applied to them. If a scale starts from a positive value (such as PANSS, which can have values from 30-210) the calculation described above in (b) should be modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.</P>
<P>4.2.2 Summary statistic: for continuous outcomes we estimated a weighted mean difference (WMD) between groups. Again, if heterogeneity was found (see section 5) we used a random effects model. In some cases, we made a post-hoc decision to use standardised mean difference (SMD) to pool data of comparable outcomes, for which different rating scales had been used in different trials. This was done in cases of two rating scales measuring the same symptom domain, but producing different scores. In these cases scores can be pooled only by using SMD.</P>
<P>4.2.3 Valid scales: we only included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>) and the instrument was either a self report or completed by an independent rater or relative (not the therapist). However, as it was expected that therapists would frequently also be the rater, we presented such data, but with a comment that they would likely be 'prone to bias'.</P>
<P>4.2.4 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). </P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but will adjust them for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>4.2.5 If possible, we transformed continuous data into dichotomous (binary) data by applying cut-off levels of at least 20% and at least 50% improvement. We decided on these levels after publishing the original protocol, but we were blinded to the data.</P>
<P>5. Investigation of heterogeneity<BR/>Firstly, we considered all the included studies within any comparison to estimate clinical heterogeneity. Then we visually inspected the graphs to investigate the possibility of statistical heterogeneity. This was supplemented employing, primarily, the I-squared statistic. This provides an estimate of the percentage of inconsistency thought to be due to chance. Where the I-squared estimate was greater than or equal to 75% this was interpreted as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). This was different compared to a previous paper publication of the review (<LINK REF="REF-Tuominen-2004" TYPE="REFERENCE">Tuominen 2004</LINK>). The reason for the change was a general decision by the Cochrane Schizophrenia Group to use the I-squared statistic in all updates of our reviews. The change led to some more positive results in favour of glutamatergic drugs.</P>
<P>6. Addressing publication bias <BR/>We entered data from all included studies into a funnel graph (trial effect against trial size) in an attempt to investigate the likelihood of overt publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
<P>7. Sensitivity analysis<BR/>We performed a sensitivity analysis to analyse whether the efficacy of glutamatergic drugs differed between trials where the glutamatergic substance had been given as an adjunct to conventional or atypical antipsychotic drugs. We also performed a sensitivity analysis to assess whether the efficacy of glutamatergic drugs differed between trials where the glutamatergic substance had been given as an adjunct to clozapine versus other antipsychotic drugs.</P>
<P>8. General <BR/>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for glutamatergic drugs.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>For substantive descriptions of studies please see Included and Excluded studies tables.</P>
<P>1. Excluded studies<BR/>We excluded 21 trials in total largely due to the fact that they were uncontrolled trials.</P>
<P>2. One study (<LINK REF="STD-Ermilov-2003" TYPE="STUDY">Ermilov 2003</LINK>) awaits assessment.</P>
<P>3. Ongoing studies<BR/>Originally, we identified four ongoing studies. One D-cycloserine trial (<LINK REF="STD-Goff-2001c" TYPE="STUDY">Goff 2001c</LINK>), one D-serine trial (<LINK REF="STD-Heresco_x002d_Levy-2000" TYPE="STUDY">Heresco-Levy 2000</LINK>) and two trials with both D-cycloserine or glycine (<LINK REF="STD-Goff-2001d" TYPE="STUDY">Goff 2001d</LINK>, <LINK REF="STD-Kee-2000" TYPE="STUDY">Kee 2000</LINK>). The update search in October 2003 identified a fifth ongoing trial with Glycine and D-cycloserine (<LINK REF="STD-Bilder-2002" TYPE="STUDY">Bilder 2002</LINK>). </P>
<P>4. Included studies<BR/>We included 18 randomised studies.</P>
<P>4.1 Study length<BR/>All trials were short-term trials with a maximum duration of 12 weeks. As regards cross-over trials 12 weeks is the duration of the first segment.</P>
<P>4.2. Study design<BR/>Twelve of the included trials were parallel-group randomised trials and six were crossover trials. The number of participants in each study ranged from six to 51 with the total number randomised totalling 358.</P>
<P>4.3 Participants<BR/>Participants were diagnosed using either DSM-III-R or DSM-IV. All were suffering from schizophrenia, some with primary deficit syndrome having permanent negative symptoms. In some trials treatment resistant patients were also included. The weighted mean age of the participants was 39.8 years and 74.5 % of participants were male.</P>
<P>4.4. Setting<BR/>The majority of trials took place in hospital (n=9), four studies did not report where the trial settings; three studies used both hospital and out-patient settings and two studies used only out-patient settings.</P>
<P>4.5 Interventions<BR/>Different preparations and dosage of glutamatergic drugs were used; D-cycloserine 10/30 mg/d (<LINK REF="STD-Rosse-1996" TYPE="STUDY">Rosse 1996</LINK>), 50 mg/d (<LINK REF="STD-Heresco_x002d_Levy-1998" TYPE="STUDY">Heresco-Levy 1998</LINK>, <LINK REF="STD-Goff-1999a" TYPE="STUDY">Goff 1999a</LINK>, <LINK REF="STD-Goff-1999b" TYPE="STUDY">Goff 1999b</LINK>, <LINK REF="STD-Duncan-2002" TYPE="STUDY">Duncan 2002</LINK>, <LINK REF="STD-Heresco_x002d_Levy-2002" TYPE="STUDY">Heresco-Levy 2002</LINK>), and 100 mg/d (<LINK REF="STD-van-Berckel-1999" TYPE="STUDY">van Berckel 1999</LINK>); D-serine 30 mg/kg per day (<LINK REF="STD-Tsai-1998" TYPE="STUDY">Tsai 1998</LINK>, <LINK REF="STD-Tsai-1999" TYPE="STUDY">Tsai 1999</LINK>); glycine 15 g/d (<LINK REF="STD-Potkin-1992" TYPE="STUDY">Potkin 1992</LINK>), 30 g/d (<LINK REF="STD-Javitt-1994" TYPE="STUDY">Javitt 1994</LINK>, <LINK REF="STD-Potkin-1999" TYPE="STUDY">Potkin 1999</LINK>), and 60 g/d (<LINK REF="STD-Heresco_x002d_Levy-1999" TYPE="STUDY">Heresco-Levy 1999</LINK>, <LINK REF="STD-Evins-2000" TYPE="STUDY">Evins 2000</LINK>, <LINK REF="STD-Javitt-2001" TYPE="STUDY">Javitt 2001</LINK>, <LINK REF="STD-Diaz-2002" TYPE="STUDY">Diaz 2002</LINK>); and ampakine CX516 2700/3600 mg/d (<LINK REF="STD-Goff-1999c" TYPE="STUDY">Goff 1999c</LINK>) and 2700 mg/d (<LINK REF="STD-Goff-2001a" TYPE="STUDY">Goff 2001a</LINK>). All studies used glutamatergic drugs to augment antipsychotic medication. Both conventional and atypical antipsychotics were used and often this was clozapine.</P>
<P>4.6 Outcomes<BR/>We were able to report dichotomous data on death, leaving the study early, relapse, hospital admission , 'no clinically significant improvement' (global effects, mental state and cognitive function - domains) and adverse effects. We used the following rating scales to assess patients' clinical state:</P>
<P>4.6.1 Global effects<BR/>4.6.1.1 Clinical Global Impressions Scale - CGI - (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement. This scale was used by <LINK REF="STD-Potkin-1992" TYPE="STUDY">Potkin 1992</LINK>, <LINK REF="STD-Tsai-1998" TYPE="STUDY">Tsai 1998</LINK> and <LINK REF="STD-van-Berckel-1999" TYPE="STUDY">van Berckel 1999</LINK>.</P>
<P>4.6.1.2 Global Assessment Scale - GAS (<LINK REF="REF-Endicott-1976" TYPE="REFERENCE">Endicott 1976</LINK>)<BR/>This is used to evaluate the overall psychological, social and occupational functioning of a person during a specified time period. The time period assessed is generally one week prior to evaluation. Scores can range from 0-100, with low scores indicating more severe symptoms. This scale was used by <LINK REF="STD-Diaz-2002" TYPE="STUDY">Diaz 2002</LINK>, <LINK REF="STD-Evins-2000" TYPE="STUDY">Evins 2000</LINK>, <LINK REF="STD-Potkin-1992" TYPE="STUDY">Potkin 1992</LINK>.</P>
<P>4.6.2 Mental state<BR/>4.6.2.1 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1961" TYPE="REFERENCE">Overall 1961</LINK>)<BR/>The original scale for assessing psychotic symptoms has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'absent' to 'extremely severe', scoring from 0-6 or 1-7. High scores indicate more severe symptoms. This scale was used by <LINK REF="STD-Diaz-2002" TYPE="STUDY">Diaz 2002</LINK>, <LINK REF="STD-Duncan-2002" TYPE="STUDY">Duncan 2002</LINK>, <LINK REF="STD-Evins-2000" TYPE="STUDY">Evins 2000</LINK>, <LINK REF="STD-Potkin-1999" TYPE="STUDY">Potkin 1999</LINK> and <LINK REF="STD-Rosse-1996" TYPE="STUDY">Rosse 1996</LINK>
</P>
<P>4.6.2.2 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from 'absent' to 'extremely severe', scoring from 1-7. This scale can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms, and negative symptoms. An additional sub-scale system has been developed for measuring cognitive symptoms etc (<LINK REF="REF-Lindenmayer-1994" TYPE="REFERENCE">Lindenmayer 1994</LINK>). High scores indicate more severe symptoms. This scale was used by <LINK REF="STD-Diaz-2002" TYPE="STUDY">Diaz 2002</LINK>, <LINK REF="STD-Evins-2000" TYPE="STUDY">Evins 2000</LINK>, <LINK REF="STD-Goff-1999a" TYPE="STUDY">Goff 1999a</LINK>, <LINK REF="STD-Heresco_x002d_Levy-1998" TYPE="STUDY">Heresco-Levy 1998</LINK>, <LINK REF="STD-Heresco_x002d_Levy-2002" TYPE="STUDY">Heresco-Levy 2002</LINK>, <LINK REF="STD-Javitt-1994" TYPE="STUDY">Javitt 1994</LINK>, <LINK REF="STD-Tsai-1998" TYPE="STUDY">Tsai 1998</LINK>, <LINK REF="STD-Tsai-1999" TYPE="STUDY">Tsai 1999</LINK> and <LINK REF="STD-van-Berckel-1999" TYPE="STUDY">van Berckel 1999</LINK>.</P>
<P>4.6.2.3 Scale for Assessment of Negative Symptoms - SANS (<LINK REF="REF-Andreasen-1982" TYPE="REFERENCE">Andreasen 1982</LINK>)<BR/>This scale, measuring negative symptoms of schizophrenia, has 24 items, each of which can be defined on a five-point scoring system varying from 'absent' to 'extremely severe', scoring from 0-5. High scores indicate more severe symptoms. This scale was used by <LINK REF="STD-Duncan-2002" TYPE="STUDY">Duncan 2002</LINK>, <LINK REF="STD-Evins-2000" TYPE="STUDY">Evins 2000</LINK>, <LINK REF="STD-Goff-1999a" TYPE="STUDY">Goff 1999a</LINK>, <LINK REF="STD-Potkin-1999" TYPE="STUDY">Potkin 1999</LINK>, <LINK REF="STD-Rosse-1996" TYPE="STUDY">Rosse 1996</LINK> <LINK REF="STD-Tsai-1998" TYPE="STUDY">Tsai 1998</LINK> and <LINK REF="STD-Tsai-1999" TYPE="STUDY">Tsai 1999</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation<BR/>All 18 trials were randomised. Allocation concealment, i.e. hiding the randomisation code from researchers, was adequate in 12 trials (category A). Reporting of allocation concealment was not common in the papers. However, we were able to obtain additional information from the study authors. We were unable to obtain information on the remaining six trials and therefore we classified them as being at moderate risk of allocation bias (category B).</P>
<P>2. Blinding<BR/>All 18 trials were double-blind and this information was often reported. Reporting of blinding includes for example use of identical tablets or capsules. In glycine and D-serine trials, the researchers had used juice solutions that appeared identical.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Please see Table of comparisons for more detailed data.</P>
<P>1. The search<BR/>An electronic search of Cochrane Schizophrenia Group's Register of Trials in May 2002 yielded 104 citations. Reference list searches and communication with trialists yielded an additional 19 citations. Sixty-seven citations were not relevant to this review, leaving 56 citations for more careful inspection. Twenty-four citations were excluded mostly because they were not reports of controlled trials. Furthermore, four ongoing trials were identified and omitted, leaving 28 citations for inclusion in the review. From these, 18 separate trials could be identified. Results from some studies had been published repeatedly and every effort was made to connect papers of the same trials to avoid citation bias. An updated search completed in October 2003, identified no new relevant clinical trials. However, we identified one additional ongoing trial and thus we have presented five ongoing trials in the table.</P>
<P>2. COMPARISON: GLUTAMATERGIC DRUG + ANTIPSYCHOTICS versus PLACEBO + ANTIPSYCHOTICS</P>
<P>2.1 Death<BR/>Fourteen trials reported on this important outcome. No deaths occurred in any of these studies (14 RCTs, n=265).</P>
<P>2.2 Leaving the study early<BR/>For ampakine CX516 we found no statistically significant difference between treatment and the control group (n=19, 2 RCTs, RR 0.22 CI 0.01 to 4.6). More studies focussed on use of D-cycloserine, but again we found no statistically significant difference between treatment and control group (n=134, 6 RCTs, RR 2.73 CI 0.9 to 8.0). Finally for glycine or D-serine, this time with most data, we again found no statistically significant difference between treatment and the control group (n=181, 9 RCTs, RR 1.13 CI 0.5 to 2.5).</P>
<P>2.3 Global effects<BR/>2.3.1 Relapse<BR/>For this outcome, when D-cycloserine was compared with the control, all on top of standard antipsychotic care, we found no statistically significant difference between treatment and control (n=73, 2 RCTs, RR 2.40 CI 0.4 to 15.4). The same applied to glycine compared with the control for the same outcome (n=22, 1 RCT, RR 0.39 CI 0.02 to 8.7).</P>
<P>2.3.2 Hospital admission<BR/>One trial (<LINK REF="STD-Goff-1999a" TYPE="STUDY">Goff 1999a</LINK>) found no statistically significant difference between D-cycloserine and the control group (n=47, RR 1.04, CI 0.1 to 15.7) and the same applies to an even smaller single trial (<LINK REF="STD-Evins-2000" TYPE="STUDY">Evins 2000</LINK>) comparing glycine with control (n=28, RR 2.63 CI 0.1 to 59.4).</P>
<P>2.3.3 No clinically significant improvement in global state<BR/>For D-cycloserine data were only available from one trial (<LINK REF="STD-van-Berckel-1999" TYPE="STUDY">van Berckel 1999</LINK>) and no patient had clinically significant improvement in either group (n=26). In the small trial of glycine versus control showed effects but these did not reach conventional levels of statistical signicance (n=58, 3 RCTs, RR 0.60 CI 0.3 to 1.4).</P>
<P>2.3.4 Average improvement score CGI <BR/>In one trial (<LINK REF="STD-van-Berckel-1999" TYPE="STUDY">van Berckel 1999</LINK>) found D-cycloserine to be equivocal (n=26, MD 0.31 CI -0.3 to 0.95) but D-serine was statistically significantly more effective than the control group (n=49, 2 RCTs, WMD -0.87 CI -1.4 to -0.3). </P>
<P>2.3.4 Average endpoint score GAS<BR/>Two trials indicated a statistically significant benefit of glycine (n=35, WMD -3.87 CI -7.7 to -0.1).</P>
<P>2.4 Mental state<BR/>2.4.1 No clinically significant improvement of overall symptoms (&lt;50% improvement of the BPRS/PANSS total score)<BR/>We found no statistically significant difference between D-cycloserine and control (n=70, 4 RCTs, RR 0.87 CI 0.6 to 1.2). Glycine also did not produce any statistically significant difference compared with the control group (n=80, 4 RCTs, RR 0.92 CI 0.8 to 1.03).</P>
<P>2.4.2 No clinically significant improvement of overall symptoms (&lt;20% improvement on BPRS/PANSS total score)<BR/>Using a less conservative cut off point of 20% still did not produced a statistically significant difference for D-cycloserine compared with the control group (n=70, 4 RCTs, RR 1.24 CI 0.9 to 1.7). However, people allocated to glycine did significantly improve in terms of psychotic symptoms compared with the control group (n=80, 4 RCTs, RR 0.63 CI 0.5 to 0.9, NNT 3 CI 2 to 8).</P>
<P>2.4.3 Worsening of overall symptoms (BPRS/PANSS total score)<BR/>We found no statistically significant difference between D-cycloserine and the control group (n=70, 4 RCTs, RR 1.35 CI 0.7 to 2.7). Glycine also produced equivocal results when compared with the control group (n=62, 3 RCTs, RR 0.63 CI 0.3 to 1.3).</P>
<P>2.4.4 Average endpoint scores of BPRS or PANSS total scores<BR/>We found no statistically significant difference between D-cycloserine and the control group (n=73, 4 RCTs, SMD = -0.08, CI -0.4 to 0.6). Glycine group did however, show a statistically significantly improvement in symptoms (n=57, 3 RCTs, SMD = -0.62, CI -1.2 to -0.1) compared with the control. </P>
<P>2.4.5 No clinically significant improvement in positive symptoms (&lt;50% improvement on BPRS/PANSS)<BR/>We found no statistically significant difference between D-cycloserine and control group (n=70, 4 RCTs, RR 0.77 CI 0.4 to 1.7). Data were analysed using random effects model due to heterogeneity being present (I-squared statistic 82%). Glycine also did not show any statistically significant difference compared with the control group (n=62, 3 RCTs, RR 1.02 CI 0.8 to 1.3).</P>
<P>2.4.6 No clinically significant improvement in positive symptoms (less than 20% improvement)<BR/>We found no statistically significant difference between D-cycloserine and the control group (n=70, 4 RCTs, RR 0.87 CI 0.7 to 1.2). Glycine also did not show any statistically significant difference compared with the control group (n=62, 3 RCTs, RR 0.81 CI 0.5 to 1.3). </P>
<P>2.4.7 Average positive symptom endpoint scores (PANSS-positive or BPRS-positive)<BR/>We found no statistically significant difference between D-cycloserine and the control group (n=73, 4 RCTs, SMD = 0.01, CI -0.5 to 0.5). Also for participants given either glycine or D-serine we again found no statistically significant difference (n=142, 7 RCTs, SMD = 0.03, CI -0.3 to 0.4) compared with the control group.</P>
<P>2.4.8 No clinically significant improvement in negative symptoms (&lt;50% improvement on SANS/PANSS)<BR/>We found that none of the 70 participants from either the D-cycloserine or control group reached 50% recovery in four trials. For those participants allocated to glycine, pooled data from three trials yielded a borderline statistically significant result favouring glycine (n=62, RR 0.87 CI 0.8 to 1.00) when compared with the control group.</P>
<P>2.4.9 No clinically significant improvement in negative symptoms (&lt;20% improvement SANS/PANSS)<BR/>Using a less conservative cut off point of 20% for the D-cycloserine group (5 RCTs) did yield a borderline statistically significant result (n=117, RR 0.77 CI 0.6 to 1.0).<BR/>However, we found that participants allocated to glycine did not show a statistically significant difference (n=62, 3 RCTs, RR 0.70 CI 0.3 to 1.7) compared with the control group . We used a random effects model due to the presence of heterogeneity I-squared statistic 75%.</P>
<P>2.4.10 Average negative symptom endpoint score (PANSS-negative or SANS)<BR/>We found no statistically significant difference between D-cycloserine and the control group (n=119, 5 RCTs, SMD= -0.11 CI -0.5 to 0.3, p = 0.55). However, when participants were allocated to either glycine or D-serine (7 RCTs) the results did significant favour glutamatergic drugs (n=132, 7 RCTs, SMD= -0.66, CI -1.02 to -0.3) compared with the control.</P>
<P>2.4.11 No clinically significant improvement in general psychopathology (&lt;50% improvement)<BR/>We found that none of the 35 participants allocated to either D-cycloserine or the control group reached 50% recovery in two trials. Glycine also did not produce any statistically significant difference compared with the control group (n=62, 3 RCTs, RR 1.04 CI 0.9 to 1.2).</P>
<P>2.4.12 No clinically significant improvement in general psychopathology (&lt;20% improvement on PANSS)<BR/>We found no statistically significant difference between D-cycloserine and the control group (n=35, 2 RCTs, RR 1.12 CI 0.8 to 1.6). However, glycine did reach statistical significance when compared with the control group (n=62, 3 RCTs, RR 0.57 CI 0.4 to 0.9, NNT 3 CI 2 to 7). </P>
<P>2.4.13 Average general psychopathology score (PANSS)<BR/>We found no statistically significant difference between D-cycloserine treatment and control group (n=51, 3 RCTs, WMD 0.72 CI -3.3 to 4.8). However, we found a statistically significant difference between glycine and the control group (n=120, 6 RCTs, WMD -3.25 CI -5.9 to -0.6). </P>
<P>2.5 Cognitive functions<BR/>2.5.1 No clinically significant improvement in cognitive functions (less than 50% improvement)<BR/>We found none of the 34 participants in either glycine or control group reached 50% recovery in two trials.</P>
<P>2.5.2 No clinically significant improvement in cognitive functions (less than 20% improvement)<BR/>Using the less conservative cut off point of 20% did not produce any statistically significant difference between glycine and the control group (n=34, 2 RCTs, RR 0.72 CI 0.4 to 1.3).</P>
<P>2.5.3 Average endpoint score (PANSS-cognitive)<BR/>We did not find any statistically significant difference when participants were allocated to either glycine or D-serine, compared with the control group (n=80, 4 RCTs, WMD -2.79 CI -6.2 to 0.6). We used a random effect model in the analysis since data were heterogeneous, I-squared statistic of 75%.</P>
<P>2.6. Adverse effects<BR/>Adverse effects were often not reported. Statistical analysis of adverse effects is reported in more detail in the tables of comparisons. We found no statistically significant differences in occurrences of adverse effects for hypertension, suicidal ideas, vague somatic discomfort, gastrointestinal dysfunction, insomnia or weakness.</P>
<P>2.7 Sensitivity analysis<BR/>We undertook a sensitivity analysis by visually inspecting the graphs. They revealed no difference between trials in which exclusively conventional antipsychotics were used versus trials using also or exclusively atypical antipsychotics. Nor was there any significant difference in pooled results of trials in which clozapine was or was not used. Because of this we found it appropriate to pool trials regardless of whether patients were treated with clozapine or not.</P>
<P>2.8 Funnel graphs<BR/>To accurately demonstrate publication bias funnel graphs should have data points from a sufficient number of trials. It was impossible to test for publication bias because of the small number of trials. Therefore we cannot exclude the possibility of publication bias.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. Strengths and weaknesses of this review<BR/>As far as we are aware, this is the first systematic review on this topic. The review gains strength from the use of rigid methods, e.g. we rated methodological quality of included trials and extracted data independently. </P>
<P>2. Generalisability<BR/>Despite the comprehensive search, the results of this review are based on a relatively small number of participants, hence the lack of certainty in our results. Lack of evidence makes it difficult to make firm conclusions on the efficacy of these glutamatergic substances. We hope that future versions of this review will be improved with the inclusion of data from the ongoing studies.</P>
<P>Participants were mostly treatment resistant with prominent negative symptoms and most of them were male (74.5%). These facts may have influenced treatment response. It is a known fact that males have a poorer outcome as regards schizophrenia than females. It should be noted that all participants received ongoing regular antipsychotic medication. Thus, this review does not tell how glutamatergic agents would work as a sole pharmacologic treatment, or whether first episode patients would benefit from glutamatergic agents.</P>
<P>3. Quality characteristics of trials<BR/>In general, although not all trials reported randomisation and allocation concealment, they were performed well. The general policy in the trials was to let hospital pharmacists conduct the randomisation and conceal it from the clinical trialists. There remains uncertainty whether glycine and D-serine trials were genuinely blinded since these liquid substances may have a distinct taste. Papers do not report how this problem was actually solved. Some authors report that they used glucose solution as placebo substance. Schizophrenia is a long-term disorder, and thus short term studies are inadequate for the assessment of the long-term efficacy and safety of drugs.</P>
<P>Diagnosis of schizophrenia was generally set using DSM-IV or DSM-III criteria. Heterogeneity (I-squared &gt;=75%) was found in three outcomes. Since heterogeneity seemed to be due to chance, we decided to pool the data on this outcome. A random effects model was then used instead of a fixed effect model in the analysis.</P>
<P>4. Effects of various mechanisms of action<BR/>4.1 Glycine activates the NMDA receptor complex together with glutamate and simultaneous partial membrane depolarisation. Since our results show that glycine administration may improve some symptoms of schizophrenia, it can be interpreted as evidence for a hypoglutamatergic model of schizophrenia.</P>
<P>4.2 D-serine also acts as an endogenous agonist on the same site of NMDA receptor complex as glycine (<LINK REF="REF-Wolosker-2002" TYPE="REFERENCE">Wolosker 2002</LINK>, <LINK REF="REF-Snyder-2000" TYPE="REFERENCE">Snyder 2000</LINK>). Sparse findings with D-serine likewise points toward the fact that NMDA-receptor based agonists may improve some symptoms of schizophrenia.</P>
<P>4.3 D-cycloserine seems to be relatively ineffective in treating schizophrenia and may even be harmful. A reason for this finding may be that D-cycloserine acts as a partial agonist on the NMDA receptor at the same site as glycine, possibly blocking the effects of endogenous co-agonists. Ongoing antipsychotic medication may also have influenced treatment response in all the included trials.</P>
<P>5. Comparison: GLUTAMATERGIC DRUG + ANTIPSYCHOTICS versus PLACEBO + ANTIPSYCHOTICS</P>
<P>5.1 Death<BR/>It is not particularly surprising that there no deaths were reported in these short-term studies and long-term data are not available.</P>
<P>5.2 Leaving the study early<BR/>Small proportions of people left these short studies (~10%). In the D-cycloserine trials this almost favoured the control group (n=134, 6 RCTs, RR 2.73 CI 0.9 to 8.0) so there could be an element of finding the additional treatment unacceptable but this finding would need replicated and we are unsure of the reasons for attrition.</P>
<P>5.3 Global effects<BR/>Overall, few people relapsed in these small studies and no statistically significant differences were found between groups, although here again the people allocated D-cycloserine did have consistently more relapses than the controls. The numbers of people admitted to hospital did not exceed (n=1) for any treatment arm, although none of the studies were longer than eight weeks. The trials measured participants' global state with GAS or CGI scales. D-serine may have a beneficial effect on global effects as measured by CGI but we are unclear of the clinical meaning of a CGI change of -0.87. We also note that these data are quite heterogeneous (I<SUP>2 </SUP>=68%). Glycine may have a beneficial effect (GAS WMD -3.87) but again we have been unable to find clear explanation of exactly what this decline in scores would mean clinically. There are insufficient data to confirm a beneficial or harmful effect of D-cycloserine on global state.</P>
<P>5.4 Mental state<BR/>We pooled the results derived from the BPRS and the PANSS total scores, as the PANSS is a further development of the BPRS and the rating scales share 18 items. We found no clear positive effects of D-cycloserine, glycine or D-serine on the overall mental state. There was no significant advantage for glycine or D-serine in terms of '&lt;50% improvement on mental state total scores', and in terms of 'any worsening of total scores'. However, applying the less conservative cut off point of &lt;20% improvement on total BPRS/PANSS scores, and also for the average mean endpoint BPRS/PANSS scores did significantly favour the glycine group compared with the control, although with a very small NNT of three. However these data were based on the results of four trials with a total number of participants of 80. This small people sample must weaken the result.</P>
<P>There was no superiority of any glutamatergic agent when participants were classified as improved or non-improved regarding positive symptoms from the BPRS or PANSS scales regardless of whether a cut off criteria of either &lt;50% or &lt;20% was used. We chose to pool the positive syndrome scores derived from the BPRS and the PANSS, as a previous research indicated a very high correlation between the PANSS and the BPRS syndrome scores (<LINK REF="REF-Bell-1992" TYPE="REFERENCE">Bell 1992</LINK>).</P>
<P>SANS and the PANSS negative symptoms domain scores dichotomised as 'no clinically significant improvement in negative symptoms' (cut off &lt;50% improvement on scale scores) were not estimable for D-cycloserine since all participants were judged to have had no clinically significant improvement and therefore both groups were equally unresponsive to negative symptoms using a 50% cut off point. However, glycine had significantly (p=0.05) fewer people recorded as having no clinical improvement. This outcome is based on a small (n=62) sample size and larger and longer studies are needed to establish if this is a sustained improvement in negative symptoms. Additionally when a lower cut off criteria (&lt;20% improvement) for negative symptoms of schizophrenia was used, as derived again from SANS and the PANSS negative symptoms domain scores, we found the glycine result to be equivocal despite the lower criteria for improvement being used. This again suggests that perhaps there are no substantive differences between the interventions on negative domain scores. Continuous negative symptom scores derived from pooled SANS and PANSS were equivocal for D-cycloserine, but did significantly favour glycine or D-serine (p=0.0004). These contradictory findings do not adequately support the use of glutamatergic drugs to treat negative symptoms and we hope further trials will clarify this issue. We chose to pool the PANSS negative syndrome score with the SANS total score, as they both cover the negative symptoms domain. </P>
<P>Three measures of general psychopathology were reported. These are measures of clinical psychiatric symptoms non-specific for schizophrenia, such as anxiety, tension, depression and psychomotor symptoms. Results measured as 'no improvement in general psychopathology' were equivocal, because no differences in terms of &lt;50% improvement in PANSS score were found, but when measured at the lower cut off point, i.e. &lt;20% improvement, did result in the glycine group having significantly fewer people not improving compared with the control. General psychopathology (PANSS) average scores also favoured glycine or D-serine group compared to control, but again numbers were relatively small (n=120). D-cycloserine was not found to be significantly different to the control arm on all three measures.</P>
<P>5.5 Cognitive function<BR/>Glycine and D-serine may or may not influence cognitive functioning as in the data analysis there was a trend towards positive effect, but analyses did not reveal statistically significant results.</P>
<P>5.6 Adverse effects<BR/>Extractable adverse effects data were minimal, partly because continuous data from adverse effect scales were skewed and therefore had to be excluded from our meta-analysis. Usable binary data on adverse effects were only reported in a few papers. Better understanding of the adverse effects of glutamatergic drugs is required before these substances can be used in clinical practice.</P>
<P>6. Efficacy spectrum<BR/>Both glycine and D-serine may modestly improve general psychopathology and negative symptoms. Regarding D-cycloserine, data analysis did not reveal any statistically significant benefit of this drug in schizophrenia.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. For people with schizophrenia<BR/>Currently, glutamatergic drugs are not available for use. To date there is no information to suggest when or if glutamatergic drugs will be available to people with schizophrenia. </P>
<P>2. For clinicians<BR/>Lack of sufficient evidence for clinical efficacy and the unavailability of glutamatergic drugs means its use in clinical trials is limited.</P>
<P>3. For managers/policy makers<BR/>Due to the limited available evidence we would not currently advocate the use of glutamatergic drugs in clinical practice</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>It is unfortunate that many of the outcomes were rendered unusable due to inadequate or absent data reporting, even though most studies post dated the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>). We hope that future work will be reported in accordance with the latest CONSORT recommendations <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>. Allocation concealment gives an assurance that selection bias is kept to a minimum and should be properly executed and described. Well reported and tested blinding could have encouraged confidence in the control of performance and detection bias. It is also important to know how many, and from which groups, people were withdrawn in order to evaluate exclusion bias. It would have been helpful if authors had presented data in a useful manner which reflects association between intervention and outcome; for example, relative risk, odds-ratio, risk or mean differences, as well as raw numbers. Binary outcomes should be calculated in preference to continuous results as they are easier to interpret. If p-values are used, the exact value should be reported. It would be useful for trials to report on economic outcomes as well as satisfaction with care.</P>
<P>2. Specific<BR/>Further clinical investigation is needed to determine how the glutamate system is implicated in schizophrenia. It is important to investigate how glutamatergic medication could be adjusted to meet the needs of people with schizophrenia. The safety of these substances is also of great interest and evidence of the effects on people with schizophrenia with prominent, primary negative symptoms is needed. We await the results of the following ongoing trials: <LINK REF="STD-Goff-2001c" TYPE="STUDY">Goff 2001c</LINK>, <LINK REF="STD-Goff-2001d" TYPE="STUDY">Goff 2001d</LINK>, <LINK REF="STD-Heresco_x002d_Levy-2000" TYPE="STUDY">Heresco-Levy 2000</LINK>, <LINK REF="STD-Kee-2000" TYPE="STUDY">Kee 2000</LINK> and <LINK REF="STD-Bilder-2002" TYPE="STUDY">Bilder 2002</LINK>.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank our key editor Dr Stefan Leucht for his patience and comments.</P>
<P>We would like to thank the following researchers for responding to requests for information: Dr. B. van Berckel, Dr. S. Akhondzadeh, Dr. D. Goff, Dr. R. Rosse, Dr. A. E. Evins, Dr. K. Kee, Dr. D. Javitt, Dr. S. Potkin, Dr. E. Duncan, Dr. R. Bilder, and Dr. P. Diaz.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Harri Tuominen - Background research, protocol production, literature searches, data extraction, data analysis, reporting.</P>
<P>Kristian Wahlbeck - Initiation, protocol production, data extraction, data analysis, contributed to reporting.</P>
<P>Jari Tiihonen - Initiation, protocol production, commented on reporting.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Diaz-2002" NAME="Diaz 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Diaz P, Bhaskara S, Dursun SM, Deakin JF</AU>
<TI>Double-blind, placebo-controlled, cross-over trial of clozapine plus glycine in refractory schizophrenia: negative results</TI>
<SO>Journal of Psyhopharmacology</SO>
<YR>submitted 2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Diaz P, Bhaskara S, Dursun SM</AU>
<TI>Double-blind, placebo-controlled, cross-over trial of clozapine plus glycine in refractory schizophrenia: negative results</TI>
<SO>European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey)</SO>
<YR>2001</YR>
<VL>11 Suppl 3</VL>
<PG>268</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Duncan-2002" NAME="Duncan 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Duncan E, Szilagyi S, Schwartz M, Kunzova A, Negi S, Stephanides M, et al</AU>
<TI>Effects of D-cycloserine on negative symptoms in schizophrenia</TI>
<SO>Young Scientists' Colloquium, Annual Meeting, American Psychiatric Association, Philadelphia, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP</AU>
<TI>Effects of D-cycloserine on negative symptoms in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>71</VL>
<NO>2-3</NO>
<PG>239-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Duncan EJ</AU>
<TI>Double-blind trial of D-cycloserine augmentation for people with schizophrenia</TI>
<SO>Personal communication</SO>
<YR>July 22, 2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Evins-2000" NAME="Evins 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC</AU>
<TI>Placebo controlled trial of glycine added to clozapine in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>5</NO>
<PG>826-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20246939"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-1999a" NAME="Goff 1999a" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Tsai G, Amico E, Coyle J</AU>
<TI>Trials of d-cycloserine added to conventional antipsychotics and clozapine in schizophrenia</TI>
<SO>Schizophrenia Research (Abstracts of the 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA)</SO>
<YR>1999</YR>
<VL>36</VL>
<PG>280</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al</AU>
<TI>A placebo controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1999</YR>
<VL>56</VL>
<PG>21-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99107270"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Goff DC, Tsai G, Levitt JJ, Amico EAU, Schoenfeld D, McCarley RW, et al</AU>
<TI>D-cycloserine added to neuroleptics in schizophrenia</TI>
<SO>Presented at Annual Meeting, American Psychiatric Association, Toronto, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-1999b" NAME="Goff 1999b" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Henderson DC, Evins AE, Amico E</AU>
<TI>A placebo controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1999</YR>
<VL>45</VL>
<PG>512-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99171120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Tsai G, Amico E, Coyle J</AU>
<TI>Trials of d-cycloserine added to conventional antipsychotics and clozapine in schizophrenia</TI>
<SO>Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA)</SO>
<YR>1999</YR>
<VL>36</VL>
<PG>280</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-1999c" NAME="Goff 1999c" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goff D, Berman I, Posever T, Leahy L, Lynch G</AU>
<TI>A preliminary dose-escalation trial of cx 516 (ampakine) added to clozapine in schizophrenia</TI>
<SO>Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA)</SO>
<YR>1999</YR>
<VL>36</VL>
<PG>280</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, et al</AU>
<TI>A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>484-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21480602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-2001a" NAME="Goff 2001a" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, et al</AU>
<TI>A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>484-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21480602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Heresco_x002d_Levy-1998" NAME="Heresco-Levy 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J</AU>
<TI>Double-blind, placebo-controlled, crossover trial of d-cycloserine adjuvant therapy for treatment-resistant schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>1</VL>
<PG>131-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Heresco_x002d_Levy-1999" NAME="Heresco-Levy 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D</AU>
<TI>Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>169</VL>
<PG>610-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M</AU>
<TI>Efficacy of high dose glycine in the treatment of enduring negative symptoms of schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1999</YR>
<VL>56</VL>
<PG>29-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99107271"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Silipo G, Javitt DC</AU>
<TI>Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<PG>731-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97146176"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Heresco-Levy U</AU>
<TI>Glycenergic augmentation of n-methyl-d- aspartate receptor-mediated neurotransmission in the treatment of schizophrenia</TI>
<SO>Presented at Annual Meeting, American Psychiatric Association, San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94311375"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Heresco_x002d_Levy-2002" NAME="Heresco-Levy 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC</AU>
<TI>Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<PG>480-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21858212"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Heresco-Levy U</AU>
<TI>Glycenergic augmentation of n-methyl-d- aspartate receptor-mediated neurotransmission in the treatment of schizophrenia</TI>
<SO>Presented at Annual Meeting, American Psychiatric Association, San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94311375"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Javitt-1994" NAME="Javitt 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Silipo G, Javitt DC</AU>
<TI>Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<PG>731-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97146176"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP</AU>
<TI>Amelioration of negative symptoms in schizophrenia by glycine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<PG>1234-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94311375"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zylberman I, Javitt DC, Zukin SR</AU>
<TI>NMDA receptor augmentation therapy in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>171</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99107332"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zylberman I, Javitt DC, Zukin SR</AU>
<TI>Pharmacological augmentation of NMDA receptor function for treatment of schizophrenia</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1995</YR>
<VL>N/A</VL>
<PG>487-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95336132"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Javitt-2001" NAME="Javitt 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, et al</AU>
<TI>Adjunctive high-dose glycine in the treatment of schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>4</VL>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zylberman I, Javitt DC, Zukin SR</AU>
<TI>NMDA receptor augmentation therapy in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>171</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99107332"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-1992" NAME="Potkin 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Potkin SG, Costa J, Roy S, Sramek J, Jin Y, Gulasekaram B</AU>
<TI>Glycine in the treatment of schizophrenia: theory and preliminary results</TI>
<SO>Novel Antipsychotic Drugs</SO>
<YR>1992</YR>
<PG>179-88</PG>
<ED>Meltzer HY</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-1999" NAME="Potkin 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Jin Y, Bunney B, Gulasekaram B, Costa J, Keator DB, et al</AU>
<TI>Clinical and brain imaging effects of adjunctive high dose glycine with clozapine in schizophrenia</TI>
<SO>Schizophrenia Research (6th International Congress on Schizophrenia Research; 1997 Apr 12-16; Colorado Springs, Colorado, USA)</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>1,2</NO>
<PG>187-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71181477"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B</AU>
<TI>Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<PG>145-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99107332"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosse-1996" NAME="Rosse 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosse RB, Fay-McCarthy M, Kendrick K, Davis RE, Deutsch SI</AU>
<TI>D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1996</YR>
<VL>19</VL>
<PG>444-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97044217"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsai-1998" NAME="Tsai 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tsai G, Yang P, Chung LC, Lange N, Coyle JT</AU>
<TI>D-serine added to antipsychotics for the treatment of schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1998</YR>
<VL>44</VL>
<PG>1081-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsai-1999" NAME="Tsai 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT</AU>
<TI>D-serine added to clozapine for the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<PG>1822-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20019180"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-van-Berckel-1999" NAME="van Berckel 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, et al</AU>
<TI>D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double blind, parallel, placebo controlled study</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>21</VL>
<PG>203-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99361033"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Cascella-1994" NAME="Cascella 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cascella NG, Macciardi F, Cavallini C, Smeraldi E</AU>
<TI>d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study</TI>
<SO>Journal of Neural Transmission</SO>
<YR>1994</YR>
<VL>95</VL>
<PG>105-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costa-1990" NAME="Costa 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Costa J, Khaled E, Sramek J, Bunney W, Potkin SG</AU>
<TI>An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>10</VL>
<PG>71-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Souza-1996" NAME="D'Souza 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>D'Souza DC, Abi-Saab D, Damon D, White J, Gil R, Krystal JH</AU>
<TI>Dose response of D-cycloserine, a partial NMDA-Glycine site agonist, in schizophrenia</TI>
<SO>Presented at 20th Congress of the Collegium Internationale Neuro-psychopharmacologicum, Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>D'Souza DC, White J, Abi-Saab D, Damon D, Gil R, Zuzarte E, et al</AU>
<TI>Dose response of oral D-cycloserine in unmedicated and medicated schizophrenics</TI>
<SO>Schizophrenia Research</SO>
<YR>1996</YR>
<VL>2,3</VL>
<PG>134</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97146176"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duncan-1997" NAME="Duncan 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Duncan EJ, Madonick S, Angrist BM, Bartlett E, Parwani AI, Rotrosen JP</AU>
<TI>N-methyl-d-aspartate modulation of prepulse inhibition</TI>
<SO>Presented at Annual Meeting, American Psychiatric Association, San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94168511"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Duncan EJ, Madonick SH, Parwani A, Angrist B, Rajan R, Chakravorty S, et al</AU>
<TI>Clinical and sensorimotor gating effects of ketamine in normals</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>25</VL>
<PG>72-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evins-2002" NAME="Evins 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Amico E, Posever TA, Toker R, Goff DC</AU>
<TI>D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>56</VL>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fincle-1958" NAME="Fincle 1958" YEAR="1958">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fincle LP, Reyna LJ</AU>
<TI>A one year study of L-glutavite on long term hospitalized, elderly, schizophrenic patients</TI>
<SO>Journal of Clinical and Experimental Psychopathology and Quarterly Review of Psychiatry and Neurology</SO>
<YR>1958</YR>
<VL>19</VL>
<NO>1</NO>
<PG>7-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-1995" NAME="Goff 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Goff DC, Tsai G, Manoach DS, Coyle JT</AU>
<TI>D-cycloserine for negative symptoms in schizophrenia</TI>
<SO>Presented at American College of Neuropsychopharmacology 33rd annual meeting, San Juan, Puerto Rico</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Tsai G, Manoach DS, Coyle JT</AU>
<TI>Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<PG>1213-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-1996" NAME="Goff 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT</AU>
<TI>D-cycloserine added to clozapine for patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>1628-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97097922"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Himwich-1955" NAME="Himwich 1955" YEAR="1955">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Himwich HE, Wolff K, Hunsicker AL, Himwich WA</AU>
<TI>Some behavioral effects associated with feeding sodium glutamate to patients with psychiatric disorders</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1955</YR>
<VL>121</VL>
<PG>40-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitzinger-1949" NAME="Kitzinger 1949" YEAR="1949">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kitzinger H, devere GA, Cartwright RW, Shapiro D</AU>
<TI>A preliminary study of the effects of glutamic acid on catatonic schizophrenics</TI>
<SO>Rorschach Research Exchange and Journal of Projective Techniques</SO>
<YR>1949</YR>
<VL>13</VL>
<PG>210-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leiderman-1996" NAME="Leiderman 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Silipo G, Javitt DC</AU>
<TI>Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<PG>731-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97146176"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC</AU>
<TI>Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial</TI>
<SO>Biological Psychiatry</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>213-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noorbala-1999" NAME="Noorbala 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini Nooshabadi H</AU>
<TI>Piracetam in the treatment of schizophrenia: Implications for the glutamate hypothesis of schizophrenia</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>1999</YR>
<VL>24</VL>
<PG>369-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-1965" NAME="Park 1965" YEAR="1965">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Park LC, Baldessarini RJ, Kety SS</AU>
<TI>Methionine effects on chronic schizophrenics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1965</YR>
<VL>12</VL>
<PG>346-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="71181477"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosse-1989" NAME="Rosse 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, et al</AU>
<TI>Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1989</YR>
<VL>12</VL>
<PG>416-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosse-1990" NAME="Rosse 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosse RB, Schwartz BL, Leighton MP, Davis RE, Deutsch SI</AU>
<TI>An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1990</YR>
<VL>13</VL>
<PG>348-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosse-1991" NAME="Rosse 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosse RB, Schwartz BL, Davis RE, Deutsch SI</AU>
<TI>An NMDA intervention strategy in schizophrenia with "low-dose" milacemide</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1991</YR>
<VL>14</VL>
<PG>268-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simeon-1970" NAME="Simeon 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simeon J, Fink M, Itil TM, Ponce D</AU>
<TI>d-Cycloserine therapy of psychosis by symptom provocation</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1970</YR>
<VL>11</VL>
<PG>80-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spitzer-1959" NAME="Spitzer 1959" YEAR="1959">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Spitzer RL</AU>
<TI>A clinical trial of monosodium glutamate (L-glutavite) on hospitalized elderly male psychotic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1959</YR>
<VL>115</VL>
<PG>936-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99107332"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamminga-1992" NAME="Tamminga 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Tamminga CA, Cascella N, Fakouhi TD, Herting RL</AU>
<TI>Enhancement of NMDA-mediated transmission in schizophrenia</TI>
<SO>Novel Antipsychotic Drugs</SO>
<YR>1992</YR>
<ED>Melzer HY</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Berckel-1996" NAME="van Berckel 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS</AU>
<TI>Efficacy and tolerance of d-cycloserine in drug-free schizophrenic patients</TI>
<SO>Biological Psychiatry</SO>
<YR>1996</YR>
<VL>40</VL>
<PG>1298-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waziri-1988" NAME="Waziri 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Waziri R</AU>
<TI>Glycine therapy of schizophrenia [letter]</TI>
<SO>Biological Psychiatry</SO>
<YR>1988</YR>
<VL>23</VL>
<PG>210-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Ermilov-2003" NAME="Ermilov 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ermilov M, Javitt DC, Lichtenberg P, Bar G, Heresco-Levy U</AU>
<TI>High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia</TI>
<SO>Journal of European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<PG>S296</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bilder-2002" NAME="Bilder 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Bilder R</AU>
<TI>Cognitive enhancement with glycinergic agents in schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada)</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-2001c" NAME="Goff 2001c" YEAR="acces">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>National Institutes of Health</AU>
<TI>Goff D: Trial of d-cycloserine in schizophrenia</TI>
<SO>http://www.clinicaltrials.gov/</SO>
<YR>(accessed 16 Feb 2001)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-2001d" NAME="Goff 2001d" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>National Institutes of Health</AU>
<TI>Goff D: Glycine and d-cycloserine in schizophrenia</TI>
<SO>http://www.clinicaltrials.gov/</SO>
<YR>(accessed 16th Feb 2001)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heresco_x002d_Levy-2000" NAME="Heresco-Levy 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Stanley Foundation Research Awards - 2000 Research Award Recipients</AU>
<TI>Heresco-Levy U: D-serine as adjunctive treatment with olanzapine or risperidone for schizophrenia</TI>
<SO>http://www.stanleyresearch.org</SO>
<YR>(accessed July 2002)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kee-2000" NAME="Kee 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Stanley Foundation Research Awards - 2000 Research Award Recipients</AU>
<TI>Kee K: D-cycloserine, glycine, or placebo as adjunctive therapy for schizophrenia</TI>
<SO>http://www.stanleyresearch.org</SO>
<YR>(accessed July 2002)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1982" NAME="Andreasen 1982" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Negative symptoms in schizophrenia: definition and reliability</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1982</YR>
<VL>39</VL>
<PG>784-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF</AU>
<TI>Improving the quality of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bell-1992" NAME="Bell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D</AU>
<TI>The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability and predictive validity</TI>
<SO>J Nerv Ment Dis</SO>
<YR>1992</YR>
<VL>Nov 180 Nov;180(11):723-8. ;180(11):723-8.</VL>
<NO>11</NO>
<PG>723-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borison-1995" NAME="Borison 1995" TYPE="JOURNAL_ARTICLE">
<AU>Borison RL</AU>
<TI>Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>Suppl 1</NO>
<PG>24-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlsson-2001" NAME="Carlsson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML</AU>
<TI>Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence</TI>
<SO>Annual Review of Pharmacology and Toxicology</SO>
<YR>2001</YR>
<VL>41</VL>
<PG>237-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Endicott-1976" NAME="Endicott 1976" TYPE="JOURNAL_ARTICLE">
<AU>Endicott J, Spitzer RL, Fleiss JL, Cohen J</AU>
<TI>The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<PG>766-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goff-2001b" NAME="Goff 2001b" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Coyle JT</AU>
<TI>The emerging role of glutamate in the pathophysiology and treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<PG>1367-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<EN>Revised</EN>
<PB>National Institute of Mental Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harvey-2001" NAME="Harvey 2001" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Keefe RS</AU>
<TI>Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>2</NO>
<PG>176-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Javitt-1999" NAME="Javitt 1999" TYPE="JOURNAL_ARTICLE">
<AU>Javitt DC</AU>
<TI>Treatment of negative and cognitive symptoms</TI>
<SO>Current Psychiatry Report</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1998" NAME="Kaplan 1998" TYPE="BOOK_SECTION">
<AU>Kaplan HI, Sadock BJ</AU>
<TI>The brain and behavior</TI>
<SO>Synopsis of Psychiatry</SO>
<YR>1998</YR>
<PG>76-139</PG>
<ED>Kaplan HI, Sadock BJ</ED>
<PB>Williams &amp; Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A, Opler LA</AU>
<TI>The positive and negative syndrome scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>261-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirkpatrick-2001" NAME="Kirkpatrick 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr</AU>
<TI>A separate disease within the syndrome of schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2001</YR>
<VL>58</VL>
<NO>2</NO>
<PG>165-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-1999" NAME="Leucht 1999" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Pitschel-Walz G, Abraham D, Kissling W</AU>
<TI>Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>1</NO>
<PG>51-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindenmayer-1994" NAME="Lindenmayer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer JP, Bernstein-Hyman R, Grochowski S</AU>
<TI>Five-factor model of schizophrenia. Initial validation</TI>
<SO>The Journal of Nervous and Mental Disease</SO>
<YR>1994</YR>
<VL>182</VL>
<PG>631-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatment of schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2000" NAME="Nelson 2000" TYPE="BOOK">
<AU>Nelson DL, Cox MM</AU>
<SO>Lehninger Principles of Biochemistry</SO>
<YR>2000</YR>
<PB>Worth Publishers</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1961" NAME="Overall 1961" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DE</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological reports</SO>
<YR>1961</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sibbald-1998" NAME="Sibbald 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sibbald B, Roberts C</AU>
<TI>Understanding controlled trials: Crossover trials</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>1719-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Snyder-2000" NAME="Snyder 2000" TYPE="JOURNAL_ARTICLE">
<AU>Snyder SH, Kim PM</AU>
<TI>D-Amino acids as putative neurotransmitters: focus on D-serine</TI>
<SO>Neurochemical research</SO>
<YR>2000</YR>
<VL>25</VL>
<PG>553-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsai-2002" NAME="Tsai 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tsai G, Coyle JT</AU>
<TI>Glutamatergic mechanisms in schizophrenia</TI>
<SO>Annual Review of Pharmacology and Toxicology</SO>
<YR>2002</YR>
<VL>42</VL>
<PG>165-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolosker-2002" NAME="Wolosker 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wolosker H, Panizzutti R, De Miranda J</AU>
<TI>Neurobiology through the looking-glass: D-serine as a new glial-derived transmitter</TI>
<SO>Neurochemistry International</SO>
<YR>2002</YR>
<VL>41</VL>
<PG>327-32</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Tuominen-2004" NAME="Tuominen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tuominen HJ, Tiihonen J, Wahlbeck K</AU>
<TI>Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>72</VL>
<PG>225-35</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Diaz-2002">
<CHAR_METHODS>
<P>Allocation: randomised, completed by the pharmacist of hospital.<BR/>Blindness: double - taste-matched placebo juice.<BR/>Duration: 28 weeks (two 12-week periods) crossover study with 2-week baseline assessment period and 2-week washout period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), considered as treatment resistant and PANSS scores in the 70th percentile or higher.<BR/>N=12.<BR/>Age: mean age 36.2 years (SD=14.3, N=5) in glycine group and 43.2 years (SD=12.0, N=6) in placebo group.<BR/>Sex: female 3, male 9.<BR/>History: clozapine as antipsychotic medication with a fixed mean dose of 576 mg/d (ranging from 400 to 900 mg/d).<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Glycine: dose 60 g/d. N=6 (first treatment phase).</P>
<P>2. Placebo. N=6 (first treatment phase).</P>
<P>Both groups were taking clozapine, which remained unchanged during the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Global effects: GAF.<BR/>Mental state: BPRS, PANSS, SANS.</P>
<P>Unable to use -<BR/>Adverse effects: ESRS, SAS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 8.3%.<BR/>12 patients entered the study. 1 patient dropped out from glycine group during the first period.<BR/>Dr. Diaz provided unpublished data and information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Duncan-2002">
<CHAR_METHODS>
<P>Allocation: randomised, concealment completed by pharmacist.<BR/>Blindness: double - identical capsules.<BR/>Duration: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV, old chart reviews), SANS score at least 30 and had prominent negative symptoms.<BR/>N=22.<BR/>Age: mean age 48.7 years (SD=12.1, N=10) in D-cycloserine group and 54.4 years (SD=11.8, N=12) in placebo group.<BR/>Sex: male 22.<BR/>History: mean age of onset 22.9 years (SD=5.1, N=9) in D-cycloserine group and 25.8 years (SD=6.8, N=12) in placebo group.<BR/>Conventional antipsychotics as patients' medication.<BR/>Setting: hospital and out-patient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-cycloserine: dose 50 mg/d. N=10.</P>
<P>2. Placebo. N=12.</P>
<P>All participants remained on stable doses of antipsychotics throughout the trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Mental state: BPRS, SANS.</P>
<P>Unable to use -<BR/>Cognitive functions: Mini Mental State Exam, Continuous Performance Test, Sternberg Short Term Memory Scanning Paradigm, Hilo Imaginary Test (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No dropouts.<BR/>Dr. Duncan provided individual patient data and information about allocation concealment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Evins-2000">
<CHAR_METHODS>
<P>Allocation: randomised, completed by the research pharmacist.<BR/>Blindness: double - taste-matched and identical-appearing lemonade mixture.<BR/>Duration: 8 weeks following a 2-week single-blind lead-in phase.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), SANS score of 27 or higher.<BR/>N=28.<BR/>Age: mean 39 years (SD=7, N=27).<BR/>Sex: female 6, male 21 (evaluated patients).<BR/>History: mean duration of illness 16 years (SD=7), clozapine monotherapy as medication, mean clozapine dose 455 mg/d (SD=116, evaluated patients).<BR/>Setting: out-patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Glycine: dose 60 g/d. N=15.</P>
<P>2. Placebo. N=13.</P>
<P>Clozapine was given to both groups throughout the trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS, PANSS, SANS.<BR/>Global effects: GAS, hospital admission.</P>
<P>Unable to use -<BR/>Depression: HAM (no usable data).<BR/>Adverse effects: SAS (no usable data).<BR/>Cognitive effects: the Stroop Test; WAIS vocabulary, information, digit span, block design subtests; California Verbal Learning Test; finger tapping; judgment of line orientation (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 7,1%.<BR/>30 patients entered the study. 28 patients completed single-blind lead-in phase, 1 dropped out on day 4 and 1 during week 5 of glycine treatment. The last dropout was included into the analysis.<BR/>Dr. Evins provided data and information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goff-1999a">
<CHAR_METHODS>
<P>Allocation: randomised, completed by the research pharmacist.<BR/>Blindness: double - identical capsules.<BR/>Duration: 8 weeks following a 2-week single-blind placebo lead-in phase.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), meeting criteria for the deficit syndrome, total SANS score of 30 or higher, SAS score &lt;8 and HAM-D score &lt;25.<BR/>N=47.<BR/>Age: mean 46.8 years (SD=12.3, N=23) in D-cycloserine group and 41.2 years (SD=8.1, N=23) in placebo group (evaluated patients).<BR/>Sex: female 12, male 34 (evaluated patients) .<BR/>History: mean duration of illness 22.3 years (SD=13.3) in D-cycloserine group and 18.5 years (SD=8.6) in placebo group (evaluated patients); conventional antipsychotics as medication, mean dose in chlorpromazine equivalents 874.0 mg/d (SD=590.0) in D-cycloserine group and 953.7 mg/d (SD=819.9) in placebo group (evaluated patients).<BR/>Setting: outpatient or hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-cycloserine: dose 50 mg/d. N=23.</P>
<P>2. Placebo. N=24.</P>
<P>Participants in both groups continued to take their usual antipsychotic medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Mental state: PANSS, SANS.<BR/>Global effects: GAS, relapse, hospital admission.<BR/>Adverse effects.</P>
<P>Unable to use -<BR/>Depression: HAM-D (skewed data).<BR/>Adverse effects: SAS, AIMS (skewed data).<BR/>Cognitive effects: SIRP, the Stroop Test, the Miller-Selfridge Test, tests of verbal fluency, digit span and finger tapping (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 17.0%.<BR/>51 patients entered the study. 48 completed single-blind lead-in phase and 1 patient dropped out because SANS score &lt;30; 7 patients dropped out of D-cycloserine treatment and 1 patient of placebo treatment after randomisation.<BR/>Dr. Goff provided information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goff-1999b">
<CHAR_METHODS>
<P>Allocation: randomised, completed by the research pharmacist.<BR/>Blindness: double - unlikely to be broken during the trial.<BR/>Duration: 13 weeks (two 6-week periods), crossover study with a 1-week single-blind placebo washout.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), total SANS score &gt;30 and had prominent negative symptoms.<BR/>N=17.<BR/>Age: mean 36.6 years (SD=9.6, N=11, completers only).<BR/>Sex: female 2, male 15.<BR/>History: mean duration of illness 14.8 years, negative symptoms despite treatment with an optimal dose of clozapine for at least 6 months; no other significant medical illnesses; clozapine as medication, mean dose 490.9 mg/d (completers only).<BR/>Setting: out-patient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-cycloserine: dose 50 mg/d. N=6 (first treatment phase).</P>
<P>2. Placebo. N=11(first treatment phase).</P>
<P>Participants in both groups continued to take clozapine throughout the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Mental state: PANSS, SANS (no usable data).<BR/>Global effect: GAS (no usable data).<BR/>Depression: HAM (no usable data).<BR/>Adverse effects: AIMS, SAS, BAS, unstructured interview (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 35.3%.<BR/>17 patients entered the study; 1 patient dropped out week 3 of D-cycloserine treatment, 3 patients dropped out during the first period of placebo treatment and 2 patients dropped out during the second placebo period.<BR/>Dr. Goff provided information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goff-1999c">
<CHAR_METHODS>
<P>Allocation: randomised, completed by the research pharmacist.<BR/>Blindness: double - no further details.<BR/>Duration: 4 weeks following a one week placebo period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=6.<BR/>Age: not mentioned (mean age for Goff 1999c and Goff 2001a is 39.8 years).<BR/>Sex: not mentioned (in Goff 1999c and Goff 2001a there was altogether 16 men and 3 women).<BR/>History: patients received clozapine monotherapy.<BR/>Setting: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CX516: dose 2700-3600 mg/d. N=4.</P>
<P>2. Placebo. N=2.</P>
<P>Participants in both groups continued to take clozapine, mean dose 406 mg/day throughout the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Adverse effects.</P>
<P>Unable to use -<BR/>Global effects: GAS (no usable data).<BR/>Mental state: PANSS, SANS (no usable data).<BR/>Depression: HAM-D (no usable data).<BR/>Adverse effects: AIMS, SAS (no usable data).<BR/>Cognitive-effects: Randt Memory Test, SKT, GDS, finger tapping tasks, The Wechsler Adult Intelligence Scale-III, Wide Range Achievement Test-Revised, Rey-Osterrieth and Taylor Complex Figure Tests, Verbal Fluency, Trail Making, Wisconsin Card Sorting Test (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No dropouts.<BR/>Dr. Goff provided information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goff-2001a">
<CHAR_METHODS>
<P>Allocation: randomised, completed by the research pharmacist.<BR/>Blindness: double - unlikely to be broken during the trial.<BR/>Duration: 4 weeks following a 1-week single-blind placebo lead-in phase.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=13.<BR/>Age: not mentioned (mean age for Goff 1999c and Goff 2001a is 39.8 years).<BR/>Sex: not mentioned (in Goff 1999c and Goff 2001a there was altogether 16 men and 3 women).<BR/>History: clozapine as medication.<BR/>Setting: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CX516: dose 2700 mg/d. N=8.</P>
<P>2. Placebo. N=5.</P>
<P>Participants in both groups continued to take clozapine throughout the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Adverse effects.</P>
<P>Unable to use -<BR/>Global effects: GAS (no usable data).<BR/>Mental state: PANSS, SANS (no usable data).<BR/>Depression: HAM-D (no usable data).<BR/>Adverse effects: AIMS, SAS (no usable data).<BR/>Cognitive-effects: Randt Memory Test, SKT, GDS, finger tapping tasks, The Wechsler Adult Intelligence Scale-III, Wide Range Achievement Test-Revised, Rey-Osterrieth and Taylor Complex Figure Tests, Verbal Fluency, Trail Making, Wisconsin Card Sorting Test (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 7.7%.<BR/>13 patients entered the study; 1 patient dropped out of placebo treatment. Dr. Goff provided information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Heresco_x002d_Levy-1998">
<CHAR_METHODS>
<P>Allocation: randomised, concealment not mentioned.<BR/>Blindness: double - no further details.<BR/>Duration: 16 weeks (two 6-week periods) crossover trial with a 2-week washout period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), considered as treatment-resistant, PANSS score in the 70th percentile or higher (based on normative data for chronic schizophrenic inpatients).<BR/>N=9.<BR/>Age: mean 39.2 years (SD=14.7, N=11).<BR/>Sex: female 6, male 3.<BR/>History: mean duration of illness 20.2 years (SD=12.9); both conventional and atypical antipsychotics as medication including clozapine.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-cycloserine: dose 50 mg/d. N=5 (first treatment phase).</P>
<P>2. Placebo. N=4 (first treatment phase).</P>
<P>All participants treated with a stable, clinically determined oral dose of conventional or atypical antipsychotic throughout the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Mental state: PANSS.</P>
<P>Unable to use -<BR/>Depression: HAM-D (no usable data).<BR/>Adverse effects: AIMS, SAS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 11.1%.<BR/>9 patients entered the study.<BR/>1 patient dropped out of D-cycloserine treatment during the first period (but was included into analysis) and 1 patient dropped out of D-cycloserine treatment during the second period.<BR/>Dr. Javitt provided patient data of this trial for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Heresco_x002d_Levy-1999">
<CHAR_METHODS>
<P>Allocation: randomised, concealment not mentioned.<BR/>Blindness: double - no further details.<BR/>Duration: 14 weeks (two 6-week periods) cross-over study with a 2-week washout period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), considered as treatment-resistant.<BR/>N=22.<BR/>Age: mean 38.8 years (SD=11.0, N=22)<BR/>Sex: female 10, male 12.<BR/>History: mean age of first symptoms 18.9 years; no other significant medical illnesses; both conventional and atypical antipsychotics as medication including clozapine, mean dose in chlorpromazine equivalents 240.0 mg/d (N=15) and mean clozapine dose 471.0 mg/d (N=7).<BR/>Setting: hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Glycine: dose 0.8 g/kg/d (mean dose 61.2 g/d). N=10 (first treatment phase).</P>
<P>2. Placebo. N=12 (first treatment phase).</P>
<P>All participants continued their usual antipsychotic medication throughout the trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Mental state: BPRS, PANSS.<BR/>Cognitive effects: PANSS-cognitive.</P>
<P>Unable to use -<BR/>Adverse effects: AIMS, SAS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 13.6%.<BR/>22 patients entered the study; 1 patient dropped out during glycine treatment and 2 patients during placebo treatment.<BR/>Dr. Javitt provided patient data of this trial for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Heresco_x002d_Levy-2002">
<CHAR_METHODS>
<P>Allocation: randomised, concealment not mentioned.<BR/>Blindness: double - no further details.<BR/>Duration: 14 weeks (two 6-week periods) crossover study with a 2-week washout period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), considered as treatment-resistant.<BR/>N=24.<BR/>Age: 40.0 years (SD=12.1, N=16, completers only).<BR/>Sex: female 6, male 10 (completers only).<BR/>History: mean duration of illness 28.8 years (SD=11.2 completers only); no other significant medical illnesses; olanzapine, risperidone and conventional antipsychotics as medication.<BR/>Setting: hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-cycloserine: dose 50 mg/d. N=8+dropouts.</P>
<P>2. Placebo. N=8+dropouts.</P>
<P>All participants treated with conventional or atypical antipsychotic throughout the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS.<BR/>Global effects: relapse.</P>
<P>Unable to use -<BR/>Depression: HAM (no usable data).<BR/>Adverse effects: AIMS, SAS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 33.3%.<BR/>24 patients entered the study; 3 patients dropped out during d-cycloserine treatment and 5 patients during placebo treatment.<BR/>Dr. Javitt provided patient data of this trial for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Javitt-1994">
<CHAR_METHODS>
<P>Allocation: randomised, completed by the research pharmacist.<BR/>Blindness: double - taste-matched placebo juice.<BR/>Duration: 8 weeks, after double-blind phase patients were offered an open-label glycine treatment for 8-week period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N=14.<BR/>Age: mean 36.0 years (SD=9.7, N=7) in glycine group and 38.1 years (SD=7.2, N=7) in placebo group.<BR/>Sex: all male.<BR/>History: mean duration of illness 15.5 years (SD=8.1) in glycine group and 20.0 years (SD=6.6) in placebo group; patients medication in chlorpromazine equivalents mean 1450 mg/d (SD=826) in glycine group and 1194 mg/d (SD=658) in placebo group; fixed doses of anticholinergic drugs during the study.<BR/>Setting: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Glycine: dose 0.4 g/kg per day (maximum dose, approximately 30 g/d). N=7.</P>
<P>2. Placebo. N=7.</P>
<P>All participants maintained on clinically orientated antipsychotics.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Mental state: PANSS.<BR/>Adverse effects.</P>
<P>Unable to use -<BR/>Adverse effects: AIMS, ESRS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No dropouts.<BR/>Dr. Javitt provided data and information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Javitt-2001">
<CHAR_METHODS>
<P>Allocation: randomised, completed by the research pharmacist.<BR/>Blindness: double - identical-appearing and taste-matched placebo juice.<BR/>Duration: 14 weeks (two 6-week periods) crossover study with a 2-week washout period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=12.<BR/>Age: mean 39.6 years (SD=5.5, N=12).<BR/>Sex: female 4, male 8.<BR/>History: mean duration of illness 20.5 years (SD=6.2); both conventional and atypical antipsychotics as medication, mean dose in chlorpromazine equivalents 1231 mg (SD=449).<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Glycine: dose 0.8 g/kg per day (maximum dose, approximately 60 g/d). N=6.</P>
<P>2. Placebo. N=6.</P>
<P>Participaints antipsychotic medication remained fixed throughout the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Cognitive effects: PANSS-cognitive.</P>
<P>Unable to use -<BR/>Mental state: PANSS (no usable data).<BR/>Adverse effects: AIMS, BAS, SAS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No dropouts.<BR/>Dr. Javitt provided information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Potkin-1992">
<CHAR_METHODS>
<P>Allocation: randomised, concealment not mentioned.<BR/>Blindness: double - no further details.<BR/>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III-R), chronically ill.<BR/>N=18.<BR/>Age: mean 32.6 years (N=11) in glycine group and 31.4 years (N=7) in placebo group.<BR/>Sex: female 3, male 15.<BR/>History: mean duration of illness 17.7 years in the glycine group and 13.7 years in the placebo group; standard antipsychotics as medication.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Glycine: dose 15 g/d. N=11.</P>
<P>2. Placebo. N=7.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Global effects: CGI.<BR/>Mental state: BPRS.</P>
<P>Unable to use -<BR/>Adverse effects: SAS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 27.8%.<BR/>18 patients entered the study.<BR/>3 dropped out from the glycine group and 2 dropped out from the placebo group. The last ratings of these dropouts were included into final analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Potkin-1999">
<CHAR_METHODS>
<P>Allocation: randomised, concealment not mentioned.<BR/>Blindness: double - taste-matched solution.<BR/>Duration: 12 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N=24.<BR/>Age: mean 35.3 years (SD=5.26, N=12) in glycine group and 34.4 years (SD=4.75, N=12) in placebo group.<BR/>Sex: female 3, male 21.<BR/>History: mean hospitalisation time 12.4 years (SD=7.2); clozapine as medication on optimal dose ranging 400-1200 mg/d.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Glycine: dose 30g/d. N=12.</P>
<P>2. Placebo. N=12.</P>
<P>All participants maintained on optimal doses of clozapine 400-1200 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS (positive symptoms).</P>
<P>Unable to use -<BR/>Mental state: BPRS (no usable data).<BR/>Adverse effects: SAS, SAFTEE (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 20.8%.<BR/>24 patients entered the study; 3 dropped out from the glycine group and 2 dropped out of the placebo group after randomisation.<BR/>Dr. Potkin provided information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rosse-1996">
<CHAR_METHODS>
<P>Allocation: randomised, completed by research pharmacist.<BR/>Blindness: double - identical tablets.<BR/>Duration: 4 weeks following a 1-week stabilized molindone treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (the Research Diagnostic Criteria), BPRS score of 35 or higher.<BR/>N=13.<BR/>Age: mean 38.1 years (SD=6.8, N=13).<BR/>Sex: not reported.<BR/>History: mean duration of illness 15.6 years (SD=5.5); molindone as treatment on fixed dose of 150 mg/d and benztropine mesylate on fixed dose of 4 mg/d.<BR/>Setting: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-cycloserine: dose 10 mg/d. N=3.</P>
<P>2. D-cycloserine: dose 30 mg/d. N=6.</P>
<P>3. Placebo. N=4.</P>
<P>All participants received molindone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Mental state: BPRS, SANS.</P>
<P>Unable to use -<BR/>Global effects: CGI (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No dropouts.<BR/>Dr. Rosse provided information about allocation concealment for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tsai-1998">
<CHAR_METHODS>
<P>Allocation: randomised, concealment not mentioned.<BR/>Blindness: double - taste-matched and identical colour juice.<BR/>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), including primary deficit syndrome and SANS score of 40 or higher.<BR/>N=31.<BR/>Age: mean 33.9 years (SD=6.6, N=14) in D-serine group and 31.7 years (SD=7.5, N=15) in placebo group (evaluated patients).<BR/>Sex: female 13, male 16 (evaluated patients).<BR/>History: mean duration of illness 10.7 years (SD=6.7) in D-serine group and 10.5 years (SD=6.0) in placebo group (evaluated patients); both conventional and atypical antipsychotics as medication, mean dose in chlorpromazine equivalents 631 mg (SD=546) in D-serine group and 1012 mg (SD=725) in placebo group (evaluated patients).<BR/>Setting: day treatment or hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-serine: dose 30 mg/kg per day. N=14.</P>
<P>2. Placebo. N=17.</P>
<P>All participants continued on a stable antipsychotic regimen.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Global effects: CGI.<BR/>Mental state: PANSS-positive, SANS.<BR/>Cognitive effects: PANSS-cognitive.<BR/>Adverse effects.</P>
<P>Unable to use -<BR/>Depression: HAM-D (no usable data).<BR/>Adverse effects: AIMS, BAS, SAS, UKU (no usable data).<BR/>Cognitive effects: WCST (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 9,7%.<BR/>31 patients entered the study.<BR/>3 patients dropped out from the placebo group after randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tsai-1999">
<CHAR_METHODS>
<P>Allocation: randomised, concealment not mentioned.<BR/>Blindness: double - no further details.<BR/>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), classified as treatment resistant, meeting criteria for the primary deficit syndrome and the SANS score of 45 or higher.<BR/>N=20.<BR/>Age: mean 42.6 years (SD=3.6, N=10) in D-serine group and 39.5 years (SD=5.5, N=10) in placebo group.<BR/>Sex: female 10, male 10.<BR/>History: mean duration of illness 20.6 years (SD=6.1) in D-serine group and 19.9 years (SD=5.7) in placebo group; clozapine as medication, mean dose 363 mg/d (SD=128) in D-serine group and 315 mg/d (SD=146) in placebo group.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-serine: dose 30 mg/kg per day. N=10.</P>
<P>2. Placebo. N=10.</P>
<P>All participants were maintained on a stable dose of clozapine throughout the study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Global effects: CGI.<BR/>Mental state: PANSS, SANS.<BR/>Cognitive functions: PANSS-cognitive.</P>
<P>Unable to use -<BR/>Adverse effects: AIMS, SAS, BARS, UKU (no usable data).<BR/>Depression: HAM (no usable data).<BR/>Cognitive functions: WCST (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No dropouts.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-Berckel-1999">
<CHAR_METHODS>
<P>Allocation: randomised, completed by the pharmacist of the hospital.<BR/>Blindness: double - identical capsules.<BR/>Duration: 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), CGI score at least "moderately severe" and patients exhibiting negative symptoms.<BR/>N=26.<BR/>Age: mean 45 years (SD=6, N=13) in D-cycloserine group and 44 years (SD=9, N=13) in placebo group.<BR/>Sex: female 4, male 22.<BR/>History: mean duration of illness 26 years (SD=8) in D-cycloserine group and 24 years (SD=4) in placebo group; typical antipsychotics as medication; patients also received anticholinergic medication.<BR/>Setting: hospital (N=19), out-patients (N=7).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-cycloserine: dose 100 mg/d. N=13.</P>
<P>2. Placebo. N=13.</P>
<P>Patients were maintained on clinically determined typical antipsychotic and anticholinergic medication and did not use antidepressants.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death.<BR/>Leaving the study early.<BR/>Mental state: PANSS.<BR/>Global effects: CGI, relapse.</P>
<P>Unable to use -<BR/>Adverse effects: ESRS (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dropouts 3,8%.<BR/>26 patients entered the study; 1 patient dropped out from the D-cycloserine group after 6 weeks. The dropout was included into analysis.<BR/>Dr. van Berckel provided data for the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tools:<BR/>DSM-III-R - Diagnostic and Statistical Manual of Mental Disorders, third edition, revised.<BR/>DSM IV - Diagnostic and Statistical Manual of Mental Disorders, fourth edition.</P>
<P>Global effect scale:<BR/>CGI - Clinical Global Impression.<BR/>GAF - Global assessment of Functioning scale.<BR/>GAS - Global Assesment Scale.</P>
<P>Mental state scales:<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>PANSS - Positive and Negative Syndrome Scale.<BR/>SANS - Scale for Assessment of Negative Symptoms.</P>
<P>Adverse-effect scales:<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>BAS/BARS - Barnes's Rating Scale for Drug-Induced Akathisia.<BR/>ESRS - Extrapyramidal Symptom Rating Scale.<BR/>SAS - Simpson-Angus Scale for assessment of extrapyramidal symptoms.<BR/>SAFTEE - Systematic Assessment for Treatment Emergent Events<BR/>UKU - Udvalg for Kliniske Undersgelser</P>
<P>Depression scale:<BR/>HAM/HAM-D - Hamilton Depression Scale.</P>
<P>Cognitive effect scales:<BR/>GDS - Gordon Diagnostic System.<BR/>SIRP - Sternberg item recognition paradigm<BR/>WCST - Wisconsin Card Sorting Test.<BR/>SKT - Short Cognitive Performance Test.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Cascella-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Costa-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-D_x0027_Souza-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia (medicated and unmedicated) and health volunteers.<BR/>Interventions: D-cycloserine 50 mg and 500 mg and placebo given over 3 days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duncan-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Evins-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fincle-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goff-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goff-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Himwich-1955">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kitzinger-1949">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leiderman-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Noorbala-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: piracetam (not glutamate receptor agonist).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Park-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosse-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosse-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosse-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simeon-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spitzer-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tamminga-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: milacemide (not glutamate receptor agonist).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Berckel-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waziri-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Bilder-2002">
<CHAR_STUDY_NAME>
<P>Cognitive enhancement with glycinercig agents in schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>People with schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Glycine.<BR/>2. D-cycloserine.<BR/>3. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cognitive functioning.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Goff-2001c">
<CHAR_STUDY_NAME>
<P>Trial of D-cycloserine in schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>People with schizophrenia having prominent, primary negative symptoms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-cycloserine.<BR/>2. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Negative symptoms.<BR/>Cognitive functioning.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>August 1996.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES>
<P>Patients receive antipsychotic medication.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Goff-2001d">
<CHAR_STUDY_NAME>
<P>Glycine and D-cycloserine in schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>People with schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Glycine.<BR/>2. D-cycloserine.<BR/>3. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Negative symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>March 1998.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES>
<P>Patients receive clozapine as antipsychotic medication.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Heresco_x002d_Levy-2000">
<CHAR_STUDY_NAME>
<P>Double-blind trial pf D-serine as adjunctive treatment with olanzapine or risperidone for the treatment of schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>People with schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-serine.<BR/>2. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES>
<P>Patients receive olanzapine or risperidone as antipsychotic medication.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Kee-2000">
<CHAR_STUDY_NAME>
<P>D-cycloserine, glycine, or placebo as adjunctive therapy for individuals with schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>People with schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. D-cycloserine<BR/>2. Glycine<BR/>3. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Negative symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Diaz-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Duncan-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Evins-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Goff-1999a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Goff-1999b">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Goff-1999c">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Goff-2001a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heresco_x002d_Levy-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heresco_x002d_Levy-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heresco_x002d_Levy-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Javitt-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Javitt-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Potkin-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Potkin-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rosse-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tsai-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tsai-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-van-Berckel-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>GLUTAMATERGIC DRUG + ANTIPSYCHOTICS versus PLACEBO + ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="136" TOTAL_2="129" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="12" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Ampakine CX516 (any dose) + clozapine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9785" O_E="0.0" SE="0.0" STUDY_ID="STD-Goff-1999c" TOTAL_1="4" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9786" O_E="0.0" SE="0.0" STUDY_ID="STD-Goff-2001a" TOTAL_1="8" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="5" TAU2="0.0" TOTAL_1="60" TOTAL_2="57" WEIGHT="0.0" Z="0.0">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9787" O_E="0.0" SE="0.0" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9788" O_E="0.0" SE="0.0" STUDY_ID="STD-Goff-1999a" TOTAL_1="23" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9789" O_E="0.0" SE="0.0" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9790" O_E="0.0" SE="0.0" STUDY_ID="STD-Rosse-1996" TOTAL_1="9" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9791" O_E="0.0" SE="0.0" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="7" TAU2="0.0" TOTAL_1="64" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Glycine or D-serine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9792" O_E="0.0" SE="0.0" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9793" O_E="0.0" SE="0.0" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9794" O_E="0.0" SE="0.0" STUDY_ID="STD-Javitt-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9795" O_E="0.0" SE="0.0" STUDY_ID="STD-Javitt-2001" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9796" O_E="0.0" SE="0.0" STUDY_ID="STD-Potkin-1992" TOTAL_1="11" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9797" O_E="0.0" SE="0.0" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9798" O_E="0.0" SE="0.0" STUDY_ID="STD-Tsai-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.158038082410469" CI_END="2.6573130841558763" CI_START="0.7925838471004378" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.451255810389951" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.4244427259236124" LOG_CI_START="-0.10095478285551363" LOG_EFFECT_SIZE="0.16174397153404935" METHOD="MH" NO="2" P_CHI2="0.6134032825037244" P_Q="0.0" P_Z="0.22752752493983408" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="169" TOTAL_2="165" WEIGHT="300.0" Z="1.2067524250727981">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.596287808202009" CI_START="0.010744043478143383" DF="0.0" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.6624072153166184" LOG_CI_START="-1.9688322428673057" LOG_EFFECT_SIZE="-0.6532125137753437" NO="1" P_CHI2="1.0" P_Z="0.33048720683587574" STUDIES="2" TAU2="0.0" TOTAL_1="12" TOTAL_2="7" WEIGHT="100.0" Z="0.9731330208419643">
<NAME>Ampakine CX516 (any dose) + clozapine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9799" O_E="0.0" SE="0.0" STUDY_ID="STD-Goff-1999c" TOTAL_1="4" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.59628780820201" CI_START="0.010744043478143374" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6624072153166186" LOG_CI_START="-1.968832242867306" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="9800" O_E="0.0" SE="1.5456030825826172" STUDY_ID="STD-Goff-2001a" TOTAL_1="8" TOTAL_2="5" VAR="2.388888888888889" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0051634522888415" CI_END="7.957151446476741" CI_START="0.9365476274766122" DF="3.0" EFFECT_SIZE="2.729881189478745" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.1718193492905967" ID="CMP-001.02.02" LOG_CI_END="0.9007576239581807" LOG_CI_START="-0.028470131984070408" LOG_EFFECT_SIZE="0.4361437459870552" NO="2" P_CHI2="0.39082995788114316" P_Z="0.06578830564226011" STUDIES="6" TAU2="0.0" TOTAL_1="66" TOTAL_2="68" WEIGHT="100.00000000000001" Z="1.8398633246812723">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9801" O_E="0.0" SE="0.0" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="54.82780214057097" CI_START="0.9731102667159666" EFFECT_SIZE="7.304347826086956" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7390008368491299" LOG_CI_START="-0.011837945432589968" LOG_EFFECT_SIZE="0.86358144570827" ORDER="9802" O_E="0.0" SE="1.0284513675040308" STUDY_ID="STD-Goff-1999a" TOTAL_1="23" TOTAL_2="24" VAR="1.0577122153209109" WEIGHT="23.63024517546872"/>
<DICH_DATA CI_END="4.66633209366438" CI_START="0.08003219287167979" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.6689756434405109" LOG_CI_START="-1.0967352833306727" LOG_EFFECT_SIZE="-0.21387981994508098" ORDER="9803" O_E="0.0" SE="1.0371873387954442" STUDY_ID="STD-Goff-1999b" TOTAL_1="6" TOTAL_2="11" VAR="1.0757575757575757" WEIGHT="51.12835656891698"/>
<DICH_DATA CI_END="48.84848114542319" CI_START="0.1279466598233339" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6888510646685808" LOG_CI_START="-0.8929710473245055" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="9804" O_E="0.0" SE="1.51657508881031" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="2.3" WEIGHT="13.169425176842251"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9805" O_E="0.0" SE="0.0" STUDY_ID="STD-Rosse-1996" TOTAL_1="9" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="9806" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="12.071973078772064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0232021854994393" CI_END="2.533620290041467" CI_START="0.5030891775160786" DF="5.0" EFFECT_SIZE="1.1289982054259475" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.4037415283468688" LOG_CI_START="-0.298355025142155" LOG_EFFECT_SIZE="0.0526932516023569" NO="3" P_CHI2="0.6964085939328777" P_Z="0.7686084061134316" STUDIES="9" TAU2="0.0" TOTAL_1="91" TOTAL_2="90" WEIGHT="100.0" Z="0.2941956483213006">
<NAME>Glycine or D-serine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="61.7381697935959" CI_START="0.1457769161296642" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898838" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="9807" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="5.225377388366938"/>
<DICH_DATA CI_END="83.62425592825048" CI_START="0.22888843419333532" EFFECT_SIZE="4.375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9223322665284344" LOG_CI_START="-0.6403761518117705" LOG_EFFECT_SIZE="0.640978057358332" ORDER="9808" O_E="0.0" SE="1.5053476105442982" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="2.2660714285714283" WEIGHT="5.573735880924733"/>
<DICH_DATA CI_END="16.8446828987975" CI_START="0.08548691647396922" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2264628397992592" LOG_CI_START="-1.0681003477040096" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="9809" O_E="0.0" SE="1.347837774610382" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="1.8166666666666667" WEIGHT="9.50068616066716"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9810" O_E="0.0" SE="0.0" STUDY_ID="STD-Javitt-1994" TOTAL_1="7" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9811" O_E="0.0" SE="0.0" STUDY_ID="STD-Javitt-2001" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.354081910115899" CI_START="0.20926501696637465" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.638896594842131" LOG_CI_START="-0.679303367018705" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="9812" O_E="0.0" SE="0.7743171827921033" STUDY_ID="STD-Potkin-1992" TOTAL_1="11" TOTAL_2="7" VAR="0.5995670995670994" WEIGHT="25.546289454238362"/>
<DICH_DATA CI_END="7.431806760962594" CI_START="0.30275275883365027" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8710944087710151" LOG_CI_START="-0.5189118906596526" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="9813" O_E="0.0" SE="0.8164965809277259" STUDY_ID="STD-Potkin-1999" TOTAL_1="12" TOTAL_2="12" VAR="0.6666666666666665" WEIGHT="20.90150955346775"/>
<DICH_DATA CI_END="3.0626665488742093" CI_START="0.009595479832057888" EFFECT_SIZE="0.17142857142857143" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.48609971510003414" LOG_CI_START="-2.017933303033298" LOG_EFFECT_SIZE="-0.765916793966632" ORDER="9814" O_E="0.0" SE="1.4708813900148656" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="17" VAR="2.1634920634920634" WEIGHT="33.25240156233506"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9815" O_E="0.0" SE="0.0" STUDY_ID="STD-Tsai-1999" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9836145118059356" CI_END="6.24279365505528" CI_START="0.3281069961395885" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4311898105001553" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.795378980301805" LOG_CI_START="-0.4839845091676727" LOG_EFFECT_SIZE="0.1556972355670661" METHOD="MH" NO="3" P_CHI2="0.6115202762794354" P_Q="0.0" P_Z="0.6333256311953637" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="49" WEIGHT="200.00000000000006" Z="0.4770512473049259">
<NAME>Global effects: 1. Relapse</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.033501508454696675" CI_END="15.400031861379853" CI_START="0.3726809957132957" DF="1.0" EFFECT_SIZE="2.3956834532374103" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.1875216193564073" LOG_CI_START="-0.42866275285195776" LOG_EFFECT_SIZE="0.37942943325222483" NO="1" P_CHI2="0.8547712570351944" P_Z="0.35742844232314186" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.00000000000003" Z="0.9202762217439985">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="21.478200608048958" CI_START="0.20278176943730142" EFFECT_SIZE="2.0869565217391304" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.331997894405131" LOG_CI_START="-0.6929710916891421" LOG_EFFECT_SIZE="0.31951340135799433" ORDER="9816" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Goff-1999a" TOTAL_1="23" TOTAL_2="24" VAR="1.414855072463768" WEIGHT="66.18705035971225"/>
<DICH_DATA CI_END="67.51227986921384" CI_START="0.13330908121359522" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8293827742293858" LOG_CI_START="-0.8751402647900609" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="9817" O_E="0.0" SE="1.5886502207249786" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="2.5238095238095233" WEIGHT="33.812949640287776"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.729381340979197" CI_START="0.01777769122868095" DF="0.0" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.9409834659599234" LOG_CI_START="-1.7501246411020248" LOG_EFFECT_SIZE="-0.40457058757105074" NO="2" P_CHI2="1.0" P_Z="0.5556556728623783" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="100.00000000000001" Z="0.5893065230360991">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="8.729381340979193" CI_START="0.01777769122868095" EFFECT_SIZE="0.3939393939393939" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9409834659599233" LOG_CI_START="-1.7501246411020248" LOG_EFFECT_SIZE="-0.40457058757105074" ORDER="9818" O_E="0.0" SE="1.5807702232881597" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="2.4988344988344986" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19223579132577417" CI_END="11.810148447343247" CI_START="0.21711872317998449" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.601313320825516" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.0722553565006314" LOG_CI_START="-0.663302723652271" LOG_EFFECT_SIZE="0.20447631642418015" METHOD="MH" NO="4" P_CHI2="0.6610622742118584" P_Q="0.0" P_Z="0.6442033842306829" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="37" WEIGHT="200.0" Z="0.46182979465314306">
<NAME>Global effects: 2. Hospital admission</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.716706127790523" CI_START="0.06927958517860539" DF="0.0" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="1.1963615327710861" LOG_CI_START="-1.1593947213830598" LOG_EFFECT_SIZE="0.018483405694013133" NO="1" P_CHI2="1.0" P_Z="0.975464137624704" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="0.03075599133656198">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="15.716706127790523" CI_START="0.06927958517860539" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1963615327710861" LOG_CI_START="-1.1593947213830598" LOG_EFFECT_SIZE="0.018483405694013133" ORDER="9819" O_E="0.0" SE="1.3837828848716724" STUDY_ID="STD-Goff-1999a" TOTAL_1="23" TOTAL_2="24" VAR="1.914855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="59.399212530180556" CI_START="0.11600532576924143" DF="0.0" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="1.7737806874716955" LOG_CI_START="-0.935522071987744" LOG_EFFECT_SIZE="0.41912930774197565" NO="2" P_CHI2="1.0" P_Z="0.5442404722588213" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.606413104014539">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="59.399212530180506" CI_START="0.11600532576924143" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.773780687471695" LOG_CI_START="-0.935522071987744" LOG_EFFECT_SIZE="0.41912930774197565" ORDER="9820" O_E="0.0" SE="1.591457852171428" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="2.532738095238095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4415182764824825" CI_START="0.24973668795823606" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.15882015301987212" LOG_CI_START="-0.6025176522525849" LOG_EFFECT_SIZE="-0.22184874961635637" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.2533539521908297" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="39" WEIGHT="100.0" Z="1.1422408193894875">
<NAME>Global effects: 3. No clinically significant improvement in global state (GAS or CGI)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="13" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9821" O_E="0.0" SE="0.0" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4415182764824825" CI_START="0.24973668795823606" DF="0.0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.15882015301987212" LOG_CI_START="-0.6025176522525849" LOG_EFFECT_SIZE="-0.22184874961635637" NO="2" P_CHI2="1.0" P_Z="0.2533539521908297" STUDIES="3" TAU2="0.0" TOTAL_1="32" TOTAL_2="26" WEIGHT="100.0" Z="1.1422408193894875">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="1.441518276482483" CI_START="0.249736687958236" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.15882015301987226" LOG_CI_START="-0.6025176522525849" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="9822" O_E="0.0" SE="0.447213595499958" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.20000000000000004" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9823" O_E="0.0" SE="0.0" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9824" O_E="0.0" SE="0.0" STUDY_ID="STD-Potkin-1992" TOTAL_1="11" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="10.658294101382467" CI_END="0.04615306809098274" CI_START="-0.7895339116379153" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3716904217734663" ESTIMABLE="YES" I2="81.23527103891247" I2_Q="86.6572210579017" ID="CMP-001.06" NO="6" P_CHI2="0.004848215935038702" P_Q="0.006188159345332234" P_Z="0.08125061001871699" Q="7.494690606353844" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="38" UNITS="" WEIGHT="200.0" Z="1.7434753867071762">
<NAME>Global effects: 4. Average improvement score (CGI-improvement, high score = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9524792020954469" CI_START="-0.3324792020954468" DF="0.0" EFFECT_SIZE="0.31000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.344304608886717" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.9456941691276">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="0.9524792020954469" CI_START="-0.3324792020954468" EFFECT_SIZE="0.31000000000000005" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.69" ORDER="9825" SD_1="1.0" SD_2="0.63" SE="0.32780153470331125" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.1636034950286227" CI_END="-0.3213115748273473" CI_START="-1.421442266691182" DF="1.0" EFFECT_SIZE="-0.8713769207592647" ESTIMABLE="YES" I2="68.39047619047619" ID="CMP-001.06.02" NO="2" P_CHI2="0.07529684943170878" P_Z="0.0019037906223583546" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="25" WEIGHT="100.0" Z="3.1048445321602887">
<NAME>D-serine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="-0.5988199476541257" CI_START="-2.201180052345874" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="4.0" ORDER="9826" SD_1="1.1" SD_2="1.1" SE="0.40877284412646364" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="15" WEIGHT="47.13769207592648"/>
<CONT_DATA CI_END="0.35655625321811" CI_START="-1.1565562532181097" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="4.3" ORDER="9827" SD_1="1.0" SD_2="0.7" SE="0.38600518131237566" STUDY_ID="STD-Tsai-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="52.86230792407352"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.478065517490593" CI_END="-0.05324127773492027" CI_START="-7.693262189188461" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.8732517334616907" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.48929990638123433" P_Q="1.0" P_Z="0.046891274621561306" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="1.9872809220355787">
<NAME>Global effects: 5. Average endpoint score (GAS, high score = good)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.478065517490593" CI_END="-0.05324127773492027" CI_START="-7.693262189188461" DF="1.0" EFFECT_SIZE="-3.8732517334616907" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="0.48929990638123433" P_Z="0.046891274621561306" STUDIES="2" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="1.9872809220355787">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="3.4777407264725912" CI_START="-8.137740726472588" EFFECT_SIZE="-2.3299999999999983" ESTIMABLE="YES" MEAN_1="-58.0" MEAN_2="-55.67" ORDER="9828" SD_1="5.48" SD_2="4.08" SE="2.963187472975681" STUDY_ID="STD-Diaz-2002" TOTAL_1="5" TOTAL_2="6" WEIGHT="43.262803916849506"/>
<CONT_DATA CI_END="0.021432119762725854" CI_START="-10.12143211976272" EFFECT_SIZE="-5.049999999999997" ESTIMABLE="YES" MEAN_1="-54.43" MEAN_2="-49.38" ORDER="9829" SD_1="7.06" SD_2="5.61" SE="2.5875129133828643" STUDY_ID="STD-Evins-2000" TOTAL_1="13" TOTAL_2="11" WEIGHT="56.73719608315049"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.18599922159849766" CI_END="1.0528224882019033" CI_START="0.7827575728788585" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9078021676208988" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.022355152863428842" LOG_CI_START="-0.10637272205842357" LOG_EFFECT_SIZE="-0.04200878459749735" METHOD="MH" NO="8" P_CHI2="0.9111939085876612" P_Q="0.0" P_Z="0.20081924450098365" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="79" TOTAL_2="71" WEIGHT="200.0" Z="1.279221068403091">
<NAME>Mental state: 1a. No clinically significant improvement of overall symptoms (&lt;50% improvement on BPRS/PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2431107822925036" CI_START="0.6126991281962566" DF="0.0" EFFECT_SIZE="0.8727272727272727" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.09450983338376763" LOG_CI_START="-0.21275273762108085" LOG_EFFECT_SIZE="-0.05912145211865664" NO="1" P_CHI2="1.0" P_Z="0.45070100211023534" STUDIES="4" TAU2="0.0" TOTAL_1="37" TOTAL_2="33" WEIGHT="100.0" Z="0.7542468741788132">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="1.2431107822925036" CI_START="0.6126991281962566" EFFECT_SIZE="0.8727272727272727" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.09450983338376763" LOG_CI_START="-0.21275273762108085" LOG_EFFECT_SIZE="-0.05912145211865664" ORDER="9830" O_E="0.0" SE="0.18048755518250442" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" VAR="0.03257575757575758" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9831" O_E="0.0" SE="0.0" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9832" O_E="0.0" SE="0.0" STUDY_ID="STD-Rosse-1996" TOTAL_1="9" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9833" O_E="0.0" SE="0.0" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0803993485096244" CI_END="1.0753662818082583" CI_START="0.789420398906206" DF="1.0" EFFECT_SIZE="0.9213664195939414" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.031556415017995734" LOG_CI_START="-0.10269165547034949" LOG_EFFECT_SIZE="-0.03556762022617686" NO="2" P_CHI2="0.776756963590491" P_Z="0.29901694171571447" STUDIES="4" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0" Z="1.0385438599679093">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9834" O_E="0.0" SE="0.0" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1331590959351334" CI_START="0.7794597328069857" EFFECT_SIZE="0.9398148148148148" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.05429088924208177" LOG_CI_START="-0.10820631571751779" LOG_EFFECT_SIZE="-0.026957713237718" ORDER="9835" O_E="0.0" SE="0.0954516625674061" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.009111019886881955" WEIGHT="55.68804382855301"/>
<DICH_DATA CI_END="1.1634437704768303" CI_START="0.6933988551778167" EFFECT_SIZE="0.8981818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.06574539857097429" LOG_CI_START="-0.1590168797121681" LOG_EFFECT_SIZE="-0.04663574057059691" ORDER="9836" O_E="0.0" SE="0.13202647485473892" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.017430990062569013" WEIGHT="44.31195617144699"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9837" O_E="0.0" SE="0.0" STUDY_ID="STD-Potkin-1992" TOTAL_1="11" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.2161569192205" CI_END="1.0924106881019042" CI_START="0.7009964913475917" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8750863154398217" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" I2="37.590031501748236" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.03838594060809432" LOG_CI_START="-0.154284155773988" LOG_EFFECT_SIZE="-0.057949107582946836" METHOD="MH" NO="9" P_CHI2="0.12946439741614602" P_Q="0.0" P_Z="0.2384017432612826" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="79" TOTAL_2="71" WEIGHT="200.0" Z="1.178991093392894">
<NAME>Mental state: 1b. No clinically significant improvement of overall symptoms (&lt;20% improvement on BPRS/PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3061745787149124" CI_END="1.677368308382071" CI_START="0.9182630226979998" DF="3.0" EFFECT_SIZE="1.2410742496050553" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.22462843334889607" LOG_CI_START="-0.03703290382581978" LOG_EFFECT_SIZE="0.09379776476153816" NO="1" P_CHI2="0.5113391852121376" P_Z="0.15996866447821886" STUDIES="4" TAU2="0.0" TOTAL_1="37" TOTAL_2="33" WEIGHT="99.99999999999999" Z="1.405176956962669">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="3.332922525881319" CI_START="0.6221566759796437" EFFECT_SIZE="1.44" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5228252185590331" LOG_CI_START="-0.20610023436853384" LOG_EFFECT_SIZE="0.15836249209524964" ORDER="9838" O_E="0.0" SE="0.4281744192888377" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" VAR="0.1833333333333334" WEIGHT="20.537124802527646"/>
<DICH_DATA CI_END="2.4403364327421704" CI_START="0.7027115543174496" EFFECT_SIZE="1.3095238095238095" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.38744970372042276" LOG_CI_START="-0.15322290552773593" LOG_EFFECT_SIZE="0.11711339909634337" ORDER="9839" O_E="0.0" SE="0.3175937670449482" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="0.10086580086580083" WEIGHT="17.251184834123222"/>
<DICH_DATA CI_END="4.865648135280239" CI_START="0.6495524828941343" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.6871406992451382" LOG_CI_START="-0.18738575281193842" LOG_EFFECT_SIZE="0.24987747321659987" ORDER="9840" O_E="0.0" SE="0.5137011669140813" STUDY_ID="STD-Rosse-1996" TOTAL_1="9" TOTAL_2="4" VAR="0.26388888888888884" WEIGHT="12.511848341232227"/>
<DICH_DATA CI_END="1.3879125342023158" CI_START="0.7205064983253695" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.14236209788382576" LOG_CI_START="-0.1423620978838257" LOG_EFFECT_SIZE="0.0" ORDER="9841" O_E="0.0" SE="0.16724840200141813" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.02797202797202797" WEIGHT="49.6998420221169"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.16857465668229" CI_END="0.8822350529995578" CI_START="0.4546448352324414" DF="3.0" EFFECT_SIZE="0.6333274116184047" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="32" I2="51.366398771713634" ID="CMP-001.09.02" LOG_CI_END="-0.05441569080851687" LOG_CI_START="-0.34232773813611883" LOG_EFFECT_SIZE="-0.19837171447231786" NO="2" P_CHI2="0.10369069086632976" P_Z="0.0069165716533918144" STUDIES="4" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.00000000000001" Z="2.7008346439550457">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="1.9983061961646733" CI_START="0.28148839305988244" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.30066203499912797" LOG_CI_START="-0.5505395082157278" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="9842" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.24999999999999997" WEIGHT="11.938177296144964"/>
<DICH_DATA CI_END="1.212860947476322" CI_START="0.3963447847103642" EFFECT_SIZE="0.6933333333333334" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.08381101256864346" LOG_CI_START="-0.40192685208244516" LOG_EFFECT_SIZE="-0.15905791975690087" ORDER="9843" O_E="0.0" SE="0.2853248261372578" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.0814102564102564" WEIGHT="31.97726061467401"/>
<DICH_DATA CI_END="0.7913283176499464" CI_START="0.13837597366851717" EFFECT_SIZE="0.33090909090909093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.10164329278498374" LOG_CI_START="-0.8589393102333545" LOG_EFFECT_SIZE="-0.480291301509169" ORDER="9844" O_E="0.0" SE="0.4448394293249171" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.1978821178821179" WEIGHT="34.19790371291526"/>
<DICH_DATA CI_END="1.440023491347377" CI_START="0.6327376117599667" EFFECT_SIZE="0.9545454545454546" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.15836957687255734" LOG_CI_START="-0.1987763490491313" LOG_EFFECT_SIZE="-0.02020338608828695" ORDER="9845" O_E="0.0" SE="0.20978928478724557" STUDY_ID="STD-Potkin-1992" TOTAL_1="11" TOTAL_2="7" VAR="0.04401154401154403" WEIGHT="21.886658376265768"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.250173367599176" CI_END="1.4861963949985264" CI_START="0.5669428410384085" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9179261443719235" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.1720762035216633" LOG_CI_START="-0.24646072430450533" LOG_EFFECT_SIZE="-0.037192260391421005" METHOD="MH" NO="10" P_CHI2="0.512150213625598" P_Q="0.0" P_Z="0.7275887539900452" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="68" TOTAL_2="64" WEIGHT="200.0" Z="0.348334811216928">
<NAME>Mental state: 2. Worsening of overall symptoms (BPRS/PANSS total score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1256068417213343" CI_END="2.675962816636449" CI_START="0.6843949169225092" DF="3.0" EFFECT_SIZE="1.353297952994693" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.4274800744762777" LOG_CI_START="-0.1646932246725843" LOG_EFFECT_SIZE="0.1313934249018467" NO="1" P_CHI2="0.546749781565087" P_Z="0.38442778828160484" STUDIES="4" TAU2="0.0" TOTAL_1="37" TOTAL_2="33" WEIGHT="100.0" Z="0.8697669448559524">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="29.45197765923085" CI_START="0.44003836176814687" EFFECT_SIZE="3.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.46911446237113" LOG_CI_START="-0.3565094608365554" LOG_EFFECT_SIZE="0.5563025007672873" ORDER="9846" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" VAR="1.15" WEIGHT="9.855951478392722"/>
<DICH_DATA CI_END="48.84848114542319" CI_START="0.1279466598233339" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6888510646685808" LOG_CI_START="-0.8929710473245055" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="9847" O_E="0.0" SE="1.51657508881031" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="2.3" WEIGHT="5.913570887035633"/>
<DICH_DATA CI_END="2.563545634366174" CI_START="0.17337098996263098" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.4088410528382531" LOG_CI_START="-0.7610235709496156" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="9848" O_E="0.0" SE="0.6871842709362767" STUDY_ID="STD-Rosse-1996" TOTAL_1="9" TOTAL_2="4" VAR="0.4722222222222221" WEIGHT="30.02274450341168"/>
<DICH_DATA CI_END="2.9638865365289027" CI_START="0.4858485580512227" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4718615739690364" LOG_CI_START="-0.3134990818737867" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="9849" O_E="0.0" SE="0.46132473684001907" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.21282051282051284" WEIGHT="54.207733131159976"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.482454380730875" CI_END="1.2701618659646976" CI_START="0.3096831740501197" DF="2.0" EFFECT_SIZE="0.6271744240714622" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" I2="19.434571868701674" ID="CMP-001.10.02" LOG_CI_END="0.10385906978731535" LOG_CI_START="-0.509082390431713" LOG_EFFECT_SIZE="-0.2026116603221988" NO="2" P_CHI2="0.289029393155398" P_Z="0.19505925808141195" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="1.2957568800696533">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="2.6656254386115874" CI_START="0.16673176883993757" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.42579912430799743" LOG_CI_START="-0.77798164241936" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="9850" O_E="0.0" SE="0.7071067811865476" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.5" WEIGHT="21.720733427362482"/>
<DICH_DATA CI_END="2.624608365044303" CI_START="0.4120995781333429" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4190645086603422" LOG_CI_START="-0.38499783006278143" LOG_EFFECT_SIZE="0.01703333929878037" ORDER="9851" O_E="0.0" SE="0.47231019793873086" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.22307692307692312" WEIGHT="38.787023977433"/>
<DICH_DATA CI_END="1.3967169004101794" CI_START="0.028638588097740534" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14510838818359562" LOG_CI_START="-1.543048396855633" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="9852" O_E="0.0" SE="0.991631652042901" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.9833333333333333" WEIGHT="39.49224259520451"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="18.95982312211769" CI_END="0.144144486752488" CI_START="-0.5825971328382085" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21922632304286024" ESTIMABLE="YES" I2="68.35413515540309" I2_Q="71.03814945968263" ID="CMP-001.11" NO="11" P_CHI2="0.004232033671140556" P_Q="0.06314413501012073" P_Z="0.23701861087507292" Q="3.452818039399501" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="66" UNITS="" WEIGHT="200.0" Z="1.1824716957015462">
<NAME>Mental state: 3. Average endpoint scores of BPRS or PANSS total scores (high score = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.658496692687981" CI_END="0.5569630118700154" CI_START="-0.40209934981978446" DF="3.0" EFFECT_SIZE="0.07743183102511546" ESTIMABLE="YES" I2="65.35195304130022" ID="CMP-001.11.01" NO="1" P_CHI2="0.03419350573868851" P_Z="0.7516357160336156" STUDIES="4" TAU2="0.0" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.0" Z="0.31648327810262683">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="0.8963410989326666" CI_START="-0.782482458106111" EFFECT_SIZE="0.05692932041327777" ESTIMABLE="YES" MEAN_1="33.5" MEAN_2="33.08" ORDER="9853" SD_1="6.43" SD_2="7.6" SE="0.42827918530164927" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" WEIGHT="32.63499765809652"/>
<CONT_DATA CI_END="0.38982891087381843" CI_START="-2.560205121575283" EFFECT_SIZE="-1.0851881053507322" ESTIMABLE="YES" MEAN_1="116.8" MEAN_2="130.0" ORDER="9854" SD_1="3.19" SD_2="16.1" SE="0.7525735308706163" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" WEIGHT="10.56913980532684"/>
<CONT_DATA CI_END="0.3507720337893864" CI_START="-1.6796755527745004" EFFECT_SIZE="-0.6644517594925571" ESTIMABLE="YES" MEAN_1="107.0" MEAN_2="115.75" ORDER="9855" SD_1="13.66" SD_2="11.11" SE="0.5179808411225406" STUDY_ID="STD-Heresco_x002d_Levy-2002" TOTAL_1="8" TOTAL_2="8" WEIGHT="22.310542391583624"/>
<CONT_DATA CI_END="1.7497058154842617" CI_START="0.11654212286755916" EFFECT_SIZE="0.9331239691759105" ESTIMABLE="YES" MEAN_1="97.54" MEAN_2="84.46" ORDER="9856" SD_1="16.49" SD_2="9.83" SE="0.4166310466669003" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" WEIGHT="34.485320144993004"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.848508390030208" CI_END="-0.06241851795833442" CI_START="-1.176147058723945" DF="2.0" EFFECT_SIZE="-0.6192827883411398" ESTIMABLE="YES" I2="70.79656056329694" ID="CMP-001.11.02" NO="2" P_CHI2="0.03257359140235472" P_Z="0.02928304855784545" STUDIES="3" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.00000000000001" Z="2.179654946365641">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="1.292714566675083" CI_START="-1.0834285101267165" EFFECT_SIZE="0.10464302827418318" ESTIMABLE="YES" MEAN_1="60.6" MEAN_2="59.33" ORDER="9857" SD_1="4.39" SD_2="14.36" SE="0.6061700866813148" STUDY_ID="STD-Diaz-2002" TOTAL_1="5" TOTAL_2="6" WEIGHT="21.969163603343333"/>
<CONT_DATA CI_END="0.4255283330462412" CI_START="-1.0966621052745424" EFFECT_SIZE="-0.3355668861141506" ESTIMABLE="YES" MEAN_1="66.57" MEAN_2="71.0" ORDER="9858" SD_1="14.68" SD_2="10.39" SE="0.3883210228166506" STUDY_ID="STD-Evins-2000" TOTAL_1="14" TOTAL_2="13" WEIGHT="53.53289364380517"/>
<CONT_DATA CI_END="-0.7633748900280468" CI_START="-3.013540803197021" EFFECT_SIZE="-1.888457846612534" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="130.2" ORDER="9859" SD_1="22.65" SD_2="23.99" SE="0.5740324646059815" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="9" TOTAL_2="10" WEIGHT="24.49794275285151"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.483195900939044" CI_END="1.6962559855672557" CI_START="0.3507934000307811" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.771385380014232" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" I2="81.76246083367656" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.2294913931625577" LOG_CI_START="-0.45494858622155154" LOG_EFFECT_SIZE="-0.11272859652949693" METHOD="MH" NO="12" P_CHI2="0.019200215771884133" P_Q="0.0" P_Z="0.5185256379844725" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.269880032964454" TOTALS="SUB" TOTAL_1="37" TOTAL_2="33" WEIGHT="100.0" Z="0.6456197647144358">
<NAME>Mental state: 4a. No clinically significant improvement in positive symptoms (&lt;50% improvement on BPRS/PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.483195900939044" CI_END="1.6962559855672557" CI_START="0.3507934000307811" DF="1.0" EFFECT_SIZE="0.771385380014232" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" I2="81.76246083367656" ID="CMP-001.12.01" LOG_CI_END="0.2294913931625577" LOG_CI_START="-0.45494858622155154" LOG_EFFECT_SIZE="-0.11272859652949693" NO="1" P_CHI2="0.019200215771884133" P_Z="0.5185256379844725" STUDIES="4" TAU2="0.269880032964454" TOTAL_1="37" TOTAL_2="33" WEIGHT="100.0" Z="0.6456197647144358">
<NAME>D-cycloserine (any dose) + different antipsychotics - heterogeneous data - random effects model</NAME>
<DICH_DATA CI_END="1.0373898061936877" CI_START="0.28679736332542644" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.015941976127604517" LOG_CI_START="-0.5424248456767673" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="9860" O_E="0.0" SE="0.3279874350882325" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" VAR="0.10757575757575756" WEIGHT="42.82327234161619"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9861" O_E="0.0" SE="0.0" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9862" O_E="0.0" SE="0.0" STUDY_ID="STD-Rosse-1996" TOTAL_1="9" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2484742686886925" CI_START="0.8009776613580735" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.09637959588106189" LOG_CI_START="-0.09637959588106192" LOG_EFFECT_SIZE="0.0" ORDER="9863" O_E="0.0" SE="0.1132277034144595" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.012820512820512803" WEIGHT="57.17672765838382"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9969154882968012" CI_END="1.3482371529733017" CI_START="0.772804848906689" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.020746887966805" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.12976629069252993" LOG_CI_START="-0.11193016163550851" LOG_EFFECT_SIZE="0.00891806452851071" METHOD="MH" NO="13" P_CHI2="0.3180582703456264" P_Q="0.0" P_Z="0.8849977413849559" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.14463667231624877">
<NAME>Mental state: 4b. No clinically significant improvement in positive symptoms (&lt;50% improvement on BPRS/PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9969154882968012" CI_END="1.3482371529733017" CI_START="0.772804848906689" DF="1.0" EFFECT_SIZE="1.020746887966805" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.12976629069252993" LOG_CI_START="-0.11193016163550851" LOG_EFFECT_SIZE="0.00891806452851071" NO="1" P_CHI2="0.3180582703456264" P_Z="0.8849977413849559" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.14463667231624877">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="1.3112596226077011" CI_START="0.5460217938664846" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.11768868825983524" LOG_CI_START="-0.26279002255705874" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="9864" O_E="0.0" SE="0.22349507813383718" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.04995004995004998" WEIGHT="37.75933609958506"/>
<DICH_DATA CI_END="1.611398200404456" CI_START="0.7877492834850927" EFFECT_SIZE="1.1266666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.20720287429198736" LOG_CI_START="-0.1036119831760027" LOG_EFFECT_SIZE="0.051795445557992315" ORDER="9865" O_E="0.0" SE="0.18257418583505539" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.03333333333333334" WEIGHT="62.24066390041493"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9866" O_E="0.0" SE="0.0" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.048861735398917" CI_END="1.1151045360675127" CI_START="0.6497800483801784" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8512183500106801" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" I2="40.29174489620129" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.04731558245971036" LOG_CI_START="-0.18723362788087985" LOG_EFFECT_SIZE="-0.06995902271058477" METHOD="MH" NO="14" P_CHI2="0.12260945758632369" P_Q="0.0" P_Z="0.24232412386909463" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="68" TOTAL_2="64" WEIGHT="200.0" Z="1.1691974124087416">
<NAME>Mental state: 4c. No clinically significant improvement in positive symptoms (&lt;20% improvement on BPRS/PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2028468186157117" CI_END="1.1886077778934347" CI_START="0.6499363343506188" DF="3.0" EFFECT_SIZE="0.8789308176100628" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" I2="6.333328757301707" ID="CMP-001.14.01" LOG_CI_END="0.07503856782455276" LOG_CI_START="-0.187129183348534" LOG_EFFECT_SIZE="-0.05604530776199065" NO="1" P_CHI2="0.36139509699998573" P_Z="0.4020371514675364" STUDIES="4" TAU2="0.0" TOTAL_1="37" TOTAL_2="33" WEIGHT="100.0" Z="0.8379885338638959">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="1.6817840951466598" CI_START="0.27958647188398394" EFFECT_SIZE="0.6857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.22577024098332618" LOG_CI_START="-0.5534838462606655" LOG_EFFECT_SIZE="-0.1638568026386696" ORDER="9867" O_E="0.0" SE="0.45773770821706344" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" VAR="0.2095238095238095" WEIGHT="24.764150943396224"/>
<DICH_DATA CI_END="2.181943904149058" CI_START="0.5214514340236913" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.3388435810682335" LOG_CI_START="-0.28278613386774637" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="9868" O_E="0.0" SE="0.3651483716701106" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="0.13333333333333325" WEIGHT="12.971698113207546"/>
<DICH_DATA CI_END="1.149946794222802" CI_START="0.32476006020422854" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.06067774686666269" LOG_CI_START="-0.4884373867568247" LOG_EFFECT_SIZE="-0.21387981994508098" ORDER="9869" O_E="0.0" SE="0.3225529476541859" STUDY_ID="STD-Rosse-1996" TOTAL_1="9" TOTAL_2="4" VAR="0.10404040404040399" WEIGHT="23.349056603773583"/>
<DICH_DATA CI_END="1.6042194076421685" CI_START="0.7542609160790669" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.20526376607519548" LOG_CI_START="-0.12247839575874538" LOG_EFFECT_SIZE="0.04139268515822507" ORDER="9870" O_E="0.0" SE="0.19251736821112286" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.03706293706293706" WEIGHT="38.91509433962264"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.382014146838382" CI_END="1.3362291018542183" CI_START="0.4935836693438384" DF="2.0" EFFECT_SIZE="0.812121212121212" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" I2="68.66193095183297" ID="CMP-001.14.02" LOG_CI_END="0.1258809260594036" LOG_CI_START="-0.306639217757601" LOG_EFFECT_SIZE="-0.0903791458490987" NO="2" P_CHI2="0.0411304804265068" P_Z="0.4127260829075945" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.8191057611997488">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="1.441518276482483" CI_START="0.249736687958236" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.15882015301987226" LOG_CI_START="-0.6025176522525849" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="9871" O_E="0.0" SE="0.447213595499958" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.20000000000000004" WEIGHT="27.450980392156865"/>
<DICH_DATA CI_END="6.940040879012617" CI_START="0.7696258078325829" EFFECT_SIZE="2.311111111111111" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.841362028592797" LOG_CI_START="-0.11372037754592369" LOG_EFFECT_SIZE="0.36382082552343664" ORDER="9872" O_E="0.0" SE="0.5610201331000428" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.31474358974358974" WEIGHT="17.647058823529413"/>
<DICH_DATA CI_END="0.9500357008739403" CI_START="0.20042743969024984" EFFECT_SIZE="0.43636363636363634" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.0222600742888085" LOG_CI_START="-0.6980428212764671" LOG_EFFECT_SIZE="-0.36015144778263786" ORDER="9873" O_E="0.0" SE="0.3969581307590986" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.1575757575757576" WEIGHT="54.90196078431373"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="14.00377251407415" CI_END="0.2965754227804979" CI_START="-0.2503981929311199" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.02308861492468901" ESTIMABLE="YES" I2="28.590670907073473" I2_Q="0.0" ID="CMP-001.15" NO="15" P_CHI2="0.17281970928708223" P_Q="0.9276358195675354" P_Z="0.8685769628413043" Q="0.008248226416705862" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="107" TOTAL_2="108" UNITS="" WEIGHT="200.0" Z="0.16546631283642466">
<NAME>Mental state: 5. Average positive symptom endpoint scores (PANSS positive or BPRS positive, high score = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.836565558297359" CI_END="0.47537032523567263" CI_START="-0.4646160828771065" DF="3.0" EFFECT_SIZE="0.005377121179283091" ESTIMABLE="YES" I2="37.97251450766842" ID="CMP-001.15.01" NO="1" P_CHI2="0.18416343857879125" P_Z="0.9821100138606631" STUDIES="4" TAU2="0.0" TOTAL_1="36" TOTAL_2="37" WEIGHT="100.0" Z="0.0224236515782427">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="0.6316459350504384" CI_START="-1.0523655730841988" EFFECT_SIZE="-0.21035981901688022" ESTIMABLE="YES" MEAN_1="15.4" MEAN_2="16.7" ORDER="9874" SD_1="6.0" SD_2="5.9" SE="0.42960266653313656" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" WEIGHT="31.15681371699541"/>
<CONT_DATA CI_END="0.7435124082766694" CI_START="-1.9971418465018025" EFFECT_SIZE="-0.6268147191125665" ESTIMABLE="YES" MEAN_1="26.8" MEAN_2="28.25" ORDER="9875" SD_1="2.59" SD_2="0.96" SE="0.6991593407828927" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" WEIGHT="11.763448242707709"/>
<CONT_DATA CI_END="0.5443186101063225" CI_START="-1.4485915461790628" EFFECT_SIZE="-0.4521364680363702" ESTIMABLE="YES" MEAN_1="24.25" MEAN_2="26.25" ORDER="9876" SD_1="4.59" SD_2="3.73" SE="0.5084047900893094" STUDY_ID="STD-Heresco_x002d_Levy-2002" TOTAL_1="8" TOTAL_2="8" WEIGHT="22.246808014020367"/>
<CONT_DATA CI_END="1.50038139282401" CI_START="-0.09229143308368992" EFFECT_SIZE="0.70404497987016" ESTIMABLE="YES" MEAN_1="20.77" MEAN_2="17.92" ORDER="9877" SD_1="3.96" SD_2="3.88" SE="0.4063015541281625" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" WEIGHT="34.832930026276514"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.158958729360085" CI_END="0.36843903919192184" CI_START="-0.3041270431018925" DF="6.0" EFFECT_SIZE="0.03215599804501466" ESTIMABLE="YES" I2="34.490369732027325" ID="CMP-001.15.02" NO="2" P_CHI2="0.16483381848073275" P_Z="0.8513350018908614" STUDIES="7" TAU2="0.0" TOTAL_1="71" TOTAL_2="71" WEIGHT="100.0" Z="0.18741533275130715">
<NAME>Glycine or D-serine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="0.9939361763730512" CI_START="-1.3886080428436676" EFFECT_SIZE="-0.19733593323530815" ESTIMABLE="YES" MEAN_1="15.2" MEAN_2="16.17" ORDER="9878" SD_1="2.86" SD_2="5.46" SE="0.6078030611812063" STUDY_ID="STD-Diaz-2002" TOTAL_1="5" TOTAL_2="6" WEIGHT="7.968709307425756"/>
<CONT_DATA CI_END="0.7752189226722037" CI_START="-0.7346433636252687" EFFECT_SIZE="0.020287779523467494" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="13.92" ORDER="9879" SD_1="4.1" SD_2="3.5" SE="0.38517602828599745" STUDY_ID="STD-Evins-2000" TOTAL_1="14" TOTAL_2="13" WEIGHT="19.84244792392595"/>
<CONT_DATA CI_END="-0.19340356094823485" CI_START="-2.1846748644582257" EFFECT_SIZE="-1.1890392127032303" ESTIMABLE="YES" MEAN_1="21.22" MEAN_2="27.3" ORDER="9880" SD_1="4.49" SD_2="5.21" SE="0.5079867077193471" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="9" TOTAL_2="10" WEIGHT="11.407987946592156"/>
<CONT_DATA CI_END="1.316664073933053" CI_START="-0.7911694616958271" EFFECT_SIZE="0.26274730611861297" ESTIMABLE="YES" MEAN_1="24.3" MEAN_2="22.2" ORDER="9881" SD_1="5.4" SD_2="9.1" SE="0.5377225174174634" STUDY_ID="STD-Javitt-1994" TOTAL_1="7" TOTAL_2="7" WEIGHT="10.181160974870648"/>
<CONT_DATA CI_END="1.681287581203052" CI_START="-0.07679743735626599" EFFECT_SIZE="0.802245071923393" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="10.5" ORDER="9882" SD_1="5.7" SD_2="5.0" SE="0.44849931744329696" STUDY_ID="STD-Potkin-1999" TOTAL_1="12" TOTAL_2="10" WEIGHT="14.634914097879662"/>
<CONT_DATA CI_END="0.8814830357957406" CI_START="-0.5776347993445246" EFFECT_SIZE="0.151924118225608" ESTIMABLE="YES" MEAN_1="16.1" MEAN_2="15.1" ORDER="9883" SD_1="6.8" SD_2="6.0" SE="0.37223077736366594" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="15" WEIGHT="21.24658777947542"/>
<CONT_DATA CI_END="0.8973677578846693" CI_START="-0.8557364427346219" EFFECT_SIZE="0.02081565757502366" ESTIMABLE="YES" MEAN_1="20.3" MEAN_2="20.2" ORDER="9884" SD_1="4.7" SD_2="4.5" SE="0.44722867727355026" STUDY_ID="STD-Tsai-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="14.718191969830414"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.84873644265966" CI_END="1.0323493704633115" CI_START="0.7378730683437992" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.87277877929436" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.013826697278671177" LOG_CI_START="-0.13201834069600996" LOG_EFFECT_SIZE="-0.05909582170866939" METHOD="MH" NO="16" P_CHI2="0.6541829713428029" P_Q="0.0" P_Z="0.11220969904072461" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="68" TOTAL_2="64" WEIGHT="100.0" Z="1.588339017826576">
<NAME>Mental state: 6a. No clinically significant improvement in negative symptoms (&lt;50% improvement on SANS/PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="33" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="37" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9885" O_E="0.0" SE="0.0" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9886" O_E="0.0" SE="0.0" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9887" O_E="0.0" SE="0.0" STUDY_ID="STD-Rosse-1996" TOTAL_1="9" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9888" O_E="0.0" SE="0.0" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.84873644265966" CI_END="1.0323493704633115" CI_START="0.7378730683437992" DF="2.0" EFFECT_SIZE="0.87277877929436" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="31" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.013826697278671177" LOG_CI_START="-0.13201834069600996" LOG_EFFECT_SIZE="-0.05909582170866939" NO="2" P_CHI2="0.6541829713428029" P_Z="0.11220969904072461" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="1.588339017826576">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="1.3112596226077011" CI_START="0.5460217938664846" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.11768868825983524" LOG_CI_START="-0.26279002255705874" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="9889" O_E="0.0" SE="0.22349507813383718" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.04995004995004998" WEIGHT="20.087561164048413"/>
<DICH_DATA CI_END="1.1331590959351334" CI_START="0.7794597328069857" EFFECT_SIZE="0.9398148148148148" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.05429088924208177" LOG_CI_START="-0.10820631571751779" LOG_EFFECT_SIZE="-0.026957713237718" ORDER="9890" O_E="0.0" SE="0.0954516625674061" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.009111019886881955" WEIGHT="44.501673963430335"/>
<DICH_DATA CI_END="1.1272920828243425" CI_START="0.5729051190890984" EFFECT_SIZE="0.8036363636363636" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.052036456883690956" LOG_CI_START="-0.24191729717399488" LOG_EFFECT_SIZE="-0.09494042014515197" ORDER="9891" O_E="0.0" SE="0.17266989022803472" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.02981489099136156" WEIGHT="35.41076487252125"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.392380505117178" CI_END="1.007720525825802" CI_START="0.5967518562415438" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7754734646390242" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" I2="8.933208419900085" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.003340104608857129" LOG_CI_START="-0.22420622141344787" LOG_EFFECT_SIZE="-0.11043305840229535" METHOD="MH" NO="17" P_CHI2="0.3554998530083505" P_Q="0.0" P_Z="0.05711572142571072" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.00000000000003" Z="1.902424187239046">
<NAME>Mental state: 6b. No clinically significant improvement in negative symptoms (&lt;20% improvement on SANS/PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.392380505117178" CI_END="1.007720525825802" CI_START="0.5967518562415438" DF="4.0" EFFECT_SIZE="0.7754734646390242" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" I2="8.933208419900085" ID="CMP-001.17.01" LOG_CI_END="0.003340104608857129" LOG_CI_START="-0.22420622141344787" LOG_EFFECT_SIZE="-0.11043305840229535" NO="1" P_CHI2="0.3554998530083505" P_Z="0.05711572142571072" STUDIES="5" TAU2="0.0" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.00000000000003" Z="1.902424187239046">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="3.332922525881319" CI_START="0.6221566759796437" EFFECT_SIZE="1.44" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5228252185590331" LOG_CI_START="-0.20610023436853384" LOG_EFFECT_SIZE="0.15836249209524964" ORDER="9892" O_E="0.0" SE="0.4281744192888377" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" VAR="0.1833333333333334" WEIGHT="10.515699543573895"/>
<DICH_DATA CI_END="0.9130374200839856" CI_START="0.29813862415606546" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.039511422900576236" LOG_CI_START="-0.5255817570393599" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="9893" O_E="0.0" SE="0.2855201203600804" STUDY_ID="STD-Goff-1999a" TOTAL_1="23" TOTAL_2="24" VAR="0.08152173913043478" WEIGHT="40.75616657143448"/>
<DICH_DATA CI_END="1.439486255584769" CI_START="0.48242519978930765" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.15820752252970433" LOG_CI_START="-0.31657001462495393" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="9894" O_E="0.0" SE="0.27888667551135854" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="0.07777777777777778" WEIGHT="11.356955507059805"/>
<DICH_DATA CI_END="1.845319466031772" CI_START="0.4281770562412305" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.26607156308280916" LOG_CI_START="-0.36837660797757177" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="9895" O_E="0.0" SE="0.37267799624996495" STUDY_ID="STD-Rosse-1996" TOTAL_1="9" TOTAL_2="4" VAR="0.1388888888888889" WEIGHT="9.609731582896758"/>
<DICH_DATA CI_END="1.16677105885247" CI_START="0.595184838684152" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.06698564813519864" LOG_CI_START="-0.22534814023044825" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="9896" O_E="0.0" SE="0.1717183143615715" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.029487179487179493" WEIGHT="27.761446795035077"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.014933995165755" CI_END="1.7122555500564969" CI_START="0.2900723423399817" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7047538421956434" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" I2="75.04658177838634" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.23356858259401264" LOG_CI_START="-0.5374936780975303" LOG_EFFECT_SIZE="-0.1519625477517588" METHOD="MH" NO="18" P_CHI2="0.01817943846787473" P_Q="0.0" P_Z="0.43979021687283437" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4445262296256468" TOTALS="SUB" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.7725475250864193">
<NAME>Mental state: 6c. No clinically significant improvement in negative symptoms (&lt;20% improvement on SANS/PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.014933995165755" CI_END="1.7122555500564969" CI_START="0.2900723423399817" DF="2.0" EFFECT_SIZE="0.7047538421956434" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" I2="75.04658177838634" ID="CMP-001.18.01" LOG_CI_END="0.23356858259401264" LOG_CI_START="-0.5374936780975303" LOG_EFFECT_SIZE="-0.1519625477517588" NO="1" P_CHI2="0.01817943846787473" P_Z="0.43979021687283437" STUDIES="3" TAU2="0.4445262296256468" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.7725475250864193">
<NAME>Glycine (any dose) + different antipsychotics - heterogeneous data - random effects model</NAME>
<DICH_DATA CI_END="2.2258791163586875" CI_START="0.44926069553853337" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.347501574857667" LOG_CI_START="-0.347501574857667" LOG_EFFECT_SIZE="0.0" ORDER="9897" O_E="0.0" SE="0.4082482904638631" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.1666666666666667" WEIGHT="33.56416138983729"/>
<DICH_DATA CI_END="1.5371885068026632" CI_START="0.7036222266908028" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.18672712868663677" LOG_CI_START="-0.15266045008907603" LOG_EFFECT_SIZE="0.01703333929878037" ORDER="9898" O_E="0.0" SE="0.19935794376846325" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.039743589743589755" WEIGHT="42.36104789308798"/>
<DICH_DATA CI_END="0.7624998337015624" CI_START="0.06243057857997594" EFFECT_SIZE="0.21818181818181817" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.11776024669921155" LOG_CI_START="-1.2046026401940264" LOG_EFFECT_SIZE="-0.661181443446619" ORDER="9899" O_E="0.0" SE="0.6384166018954689" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.40757575757575765" WEIGHT="24.074790717074727"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="20.83583987897982" CI_END="-0.13033142396321812" CI_START="-0.6450408574893309" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3876861407262745" ESTIMABLE="YES" I2="47.206351825071756" I2_Q="76.74556911954963" ID="CMP-001.19" NO="19" P_CHI2="0.035112274437491764" P_Q="0.03810682416120281" P_Z="0.0031516814898960863" Q="4.300255745414454" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="127" UNITS="" WEIGHT="200.0" Z="2.95254302188839">
<NAME>Mental state: 7. Average negative symptom endpoint scores (PANSS-negative or SANS, high score = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.502738355910591" CI_END="0.2546965675547349" CI_START="-0.4781404665606084" DF="4.0" EFFECT_SIZE="-0.11172194950293676" ESTIMABLE="YES" I2="38.48745280725858" ID="CMP-001.19.01" NO="1" P_CHI2="0.16461799368394225" P_Z="0.55010815782257" STUDIES="5" TAU2="0.0" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0" Z="0.5975980664587817">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="0.7860535351711253" CI_START="-0.8927197817110042" EFFECT_SIZE="-0.053333123269939414" ESTIMABLE="YES" MEAN_1="58.3" MEAN_2="59.1" ORDER="9900" SD_1="12.4" SD_2="15.9" SE="0.42826636869964935" STUDY_ID="STD-Duncan-2002" TOTAL_1="10" TOTAL_2="12" WEIGHT="19.05595424354098"/>
<CONT_DATA CI_END="0.1855341258780992" CI_START="-0.9828804065433203" EFFECT_SIZE="-0.39867314033261053" ESTIMABLE="YES" MEAN_1="42.8" MEAN_2="48.4" ORDER="9901" SD_1="13.4" SD_2="14.2" SE="0.29807040885386776" STUDY_ID="STD-Goff-1999a" TOTAL_1="23" TOTAL_2="23" WEIGHT="39.33878268969182"/>
<CONT_DATA CI_END="0.7347564317660175" CI_START="-2.0096120606910395" EFFECT_SIZE="-0.6374278144625111" ESTIMABLE="YES" MEAN_1="34.4" MEAN_2="40.0" ORDER="9902" SD_1="6.8" SD_2="8.98" SE="0.700106867805808" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" WEIGHT="7.1306639137836925"/>
<CONT_DATA CI_END="0.559717098157092" CI_START="-1.4308399758163628" EFFECT_SIZE="-0.43556143882963533" ESTIMABLE="YES" MEAN_1="29.13" MEAN_2="31.25" ORDER="9903" SD_1="6.29" SD_2="1.67" SE="0.5078045029589102" STUDY_ID="STD-Heresco_x002d_Levy-2002" TOTAL_1="8" TOTAL_2="8" WEIGHT="13.55393966660448"/>
<CONT_DATA CI_END="1.5647665195892608" CI_START="-0.037444531886822396" EFFECT_SIZE="0.7636609938512192" ESTIMABLE="YES" MEAN_1="28.08" MEAN_2="23.46" ORDER="9904" SD_1="7.51" SD_2="3.5" SE="0.4087348196482485" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" WEIGHT="20.920659486379027"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.032845777654776" CI_END="-0.29481064639355536" CI_START="-1.0178898315126408" DF="6.0" EFFECT_SIZE="-0.6563502389530981" ESTIMABLE="YES" I2="40.19642947803263" ID="CMP-001.19.02" NO="2" P_CHI2="0.12327569556718898" P_Z="3.734338433490983E-4" STUDIES="7" TAU2="0.0" TOTAL_1="65" TOTAL_2="67" WEIGHT="100.0" Z="3.558179674002003">
<NAME>Glycine or D-serine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="1.783808365305211" CI_START="-0.6610063256758156" EFFECT_SIZE="0.5614010198146977" ESTIMABLE="YES" MEAN_1="16.0" MEAN_2="13.67" ORDER="9905" SD_1="2.92" SD_2="4.37" SE="0.6236886775128045" STUDY_ID="STD-Diaz-2002" TOTAL_1="5" TOTAL_2="6" WEIGHT="8.747416925127292"/>
<CONT_DATA CI_END="0.3966541935367968" CI_START="-1.1278384422769698" EFFECT_SIZE="-0.36559212437008654" ESTIMABLE="YES" MEAN_1="20.29" MEAN_2="22.31" ORDER="9906" SD_1="5.66" SD_2="5.01" SE="0.38890832888735966" STUDY_ID="STD-Evins-2000" TOTAL_1="14" TOTAL_2="13" WEIGHT="22.496816100822134"/>
<CONT_DATA CI_END="-0.8150410877725565" CI_START="-3.093749906166398" EFFECT_SIZE="-1.9543954969694772" ESTIMABLE="YES" MEAN_1="25.44" MEAN_2="40.2" ORDER="9907" SD_1="7.8" SD_2="6.65" SE="0.5813139517787076" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="9" TOTAL_2="10" WEIGHT="10.069178824237808"/>
<CONT_DATA CI_END="0.5780816122981448" CI_START="-1.560751167572299" EFFECT_SIZE="-0.491334777637077" ESTIMABLE="YES" MEAN_1="18.9" MEAN_2="22.5" ORDER="9908" SD_1="7.7" SD_2="5.9" SE="0.5456306332007331" STUDY_ID="STD-Javitt-1994" TOTAL_1="7" TOTAL_2="7" WEIGHT="11.429258536878972"/>
<CONT_DATA CI_END="0.6766690878482047" CI_START="-1.6342772458880996" EFFECT_SIZE="-0.47880407901994754" ESTIMABLE="YES" MEAN_1="14.33" MEAN_2="17.33" ORDER="9909" SD_1="6.77" SD_2="4.59" SE="0.5895379588514774" STUDY_ID="STD-Javitt-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="9.790209820781847"/>
<CONT_DATA CI_END="-0.06260820432545822" CI_START="-1.5894108451031417" EFFECT_SIZE="-0.8260095247142999" ESTIMABLE="YES" MEAN_1="44.4" MEAN_2="55.7" ORDER="9910" SD_1="13.4" SD_2="13.2" SE="0.38949762669643617" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="15" WEIGHT="22.428793629970347"/>
<CONT_DATA CI_END="0.013818758299174894" CI_START="-1.8507830882510163" EFFECT_SIZE="-0.9184821649759207" ESTIMABLE="YES" MEAN_1="54.9" MEAN_2="62.8" ORDER="9911" SD_1="9.6" SD_2="6.6" SE="0.47567247695823306" STUDY_ID="STD-Tsai-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="15.038326162181601"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.417742009200456" CI_END="1.2271860487935562" CI_START="0.8710189205082487" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0338772980789095" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="45" I2="17.27818797914682" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.08891040937673214" LOG_CI_START="-0.0599724110278364" LOG_EFFECT_SIZE="0.014468999174447848" METHOD="MH" NO="20" P_CHI2="0.2985341998501192" P_Q="0.0" P_Z="0.7032377387837769" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0" Z="0.3809535203215072">
<NAME>Mental state: 8a. No clinically significant improvement in general psychopathology (&lt;50% improvement on PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="17" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9912" O_E="0.0" SE="0.0" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9913" O_E="0.0" SE="0.0" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.417742009200456" CI_END="1.2271860487935562" CI_START="0.8710189205082487" DF="2.0" EFFECT_SIZE="1.0338772980789095" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" I2="17.27818797914682" ID="CMP-001.20.02" LOG_CI_END="0.08891040937673214" LOG_CI_START="-0.0599724110278364" LOG_EFFECT_SIZE="0.014468999174447848" NO="2" P_CHI2="0.2985341998501192" P_Z="0.7032377387837769" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.3809535203215072">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="2.603533377903773" CI_START="0.8013800671018453" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.4155631498037241" LOG_CI_START="-0.09616146406870035" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="9914" O_E="0.0" SE="0.30058957126635377" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.09035409035409037" WEIGHT="15.616608138814296"/>
<DICH_DATA CI_END="1.2438544435158854" CI_START="0.8219174553274723" EFFECT_SIZE="1.011111111111111" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.0947695619654097" LOG_CI_START="-0.08517179620187229" LOG_EFFECT_SIZE="0.004798882881768708" ORDER="9915" O_E="0.0" SE="0.1056984445115498" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.011172161172161174" WEIGHT="44.618880396612276"/>
<DICH_DATA CI_END="1.1634437704768303" CI_START="0.6933988551778167" EFFECT_SIZE="0.8981818181818182" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.06574539857097429" LOG_CI_START="-0.1590168797121681" LOG_EFFECT_SIZE="-0.04663574057059691" ORDER="9916" O_E="0.0" SE="0.13202647485473892" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.017430990062569013" WEIGHT="39.76451146457344"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.715219361081724" CI_END="0.9988833764443229" CI_START="0.561093591901155" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7486434809570566" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="38" I2="54.103278021179676" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-4.8521439995191374E-4" LOG_CI_START="-0.25096469122856874" LOG_EFFECT_SIZE="-0.12572495281426035" METHOD="MH" NO="21" P_CHI2="0.06862549460875822" P_Q="0.0" P_Z="0.04911898041046052" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="49" TOTAL_2="48" WEIGHT="200.0" Z="1.9675574429800582">
<NAME>Mental state: 8b. No clinically significant improvement in general psychopathology (&lt;20% improvement on PANSS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.020260517996177223" CI_END="1.63853906677208" CI_START="0.7630764525959985" DF="1.0" EFFECT_SIZE="1.1181818181818182" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-001.21.01" LOG_CI_END="0.2144568004826774" LOG_CI_START="-0.11743194792033154" LOG_EFFECT_SIZE="0.04851242628117289" NO="1" P_CHI2="0.8868118989316511" P_Z="0.5666590514123695" STUDIES="2" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.5729787994999787">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="4.0382525668689" CI_START="0.35658988043843887" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6061934777991137" LOG_CI_START="-0.44783098570386404" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="9917" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" VAR="0.3833333333333333" WEIGHT="18.181818181818183"/>
<DICH_DATA CI_END="1.6042194076421685" CI_START="0.7542609160790669" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.20526376607519548" LOG_CI_START="-0.12247839575874538" LOG_EFFECT_SIZE="0.04139268515822507" ORDER="9918" O_E="0.0" SE="0.19251736821112286" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" VAR="0.03706293706293706" WEIGHT="81.81818181818181"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.558341160564388" CI_END="0.8708636271904643" CI_START="0.38107222549975817" DF="2.0" EFFECT_SIZE="0.5760745963156698" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" I2="56.12438978234856" ID="CMP-001.21.02" LOG_CI_END="-0.06004984797243179" LOG_CI_START="-0.4189927036858847" LOG_EFFECT_SIZE="-0.23952127582915825" NO="2" P_CHI2="0.10236921949745703" P_Z="0.008903072043994733" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="2.6157538264586755">
<NAME>Glycine (any dose) + different antipsychotics</NAME>
<DICH_DATA CI_END="1.7718144443499428" CI_START="0.14109829660617873" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.2484182378588839" LOG_CI_START="-0.8504782291868462" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="9919" O_E="0.0" SE="0.6454972243679029" STUDY_ID="STD-Diaz-2002" TOTAL_1="6" TOTAL_2="6" VAR="0.41666666666666674" WEIGHT="15.283147600636799"/>
<DICH_DATA CI_END="1.3804466880743576" CI_START="0.5441072933854963" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.14001963913739823" LOG_CI_START="-0.2643154526350871" LOG_EFFECT_SIZE="-0.062147906748844454" ORDER="9920" O_E="0.0" SE="0.23750843439814182" STUDY_ID="STD-Evins-2000" TOTAL_1="15" TOTAL_2="13" VAR="0.05641025641025643" WEIGHT="40.937002501705706"/>
<DICH_DATA CI_END="0.7913283176499464" CI_START="0.13837597366851717" EFFECT_SIZE="0.33090909090909093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.10164329278498374" LOG_CI_START="-0.8589393102333545" LOG_EFFECT_SIZE="-0.480291301509169" ORDER="9921" O_E="0.0" SE="0.4448394293249171" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.1978821178821179" WEIGHT="43.7798498976575"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="23.17356359224879" CI_END="0.1428675508488917" CI_START="-4.268429767504363" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.062781108327736" ESTIMABLE="YES" I2="65.47790343874483" I2_Q="61.74074359161818" ID="CMP-001.22" NO="22" P_CHI2="0.003148420377714234" P_Q="0.10594125344289707" P_Z="0.0668010413874721" Q="2.613746564559264" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="85" TOTAL_2="86" UNITS="" WEIGHT="200.0" Z="1.8330102863350997">
<NAME>Mental state: 9. Average general psychopathology score (PANSS-general, high score = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.819936837728212" CI_END="4.759627192480499" CI_START="-3.310718841582478" DF="2.0" EFFECT_SIZE="0.7244541754490107" ESTIMABLE="YES" I2="70.67421520774349" ID="CMP-001.22.01" NO="1" P_CHI2="0.03304237412358202" P_Z="0.7249268820835318" STUDIES="3" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.3518818366242664">
<NAME>D-cycloserine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="4.08485611068615" CI_START="-16.384856110686147" EFFECT_SIZE="-6.149999999999999" ESTIMABLE="YES" MEAN_1="55.6" MEAN_2="61.75" ORDER="9922" SD_1="5.18" SD_2="9.36" SE="5.2219613173595985" STUDY_ID="STD-Heresco_x002d_Levy-1998" TOTAL_1="5" TOTAL_2="4" WEIGHT="15.543930250064438"/>
<CONT_DATA CI_END="2.7609300530506564" CI_START="-12.000930053050652" EFFECT_SIZE="-4.619999999999997" ESTIMABLE="YES" MEAN_1="53.63" MEAN_2="58.25" ORDER="9923" SD_1="7.37" SD_2="7.69" SE="3.7658498376860434" STUDY_ID="STD-Heresco_x002d_Levy-2002" TOTAL_1="8" TOTAL_2="8" WEIGHT="29.888363901695126"/>
<CONT_DATA CI_END="11.072536011918434" CI_START="0.14746398808156513" EFFECT_SIZE="5.609999999999999" ESTIMABLE="YES" MEAN_1="48.69" MEAN_2="43.08" ORDER="9924" SD_1="7.2" SD_2="7.01" SE="2.787059382216317" STUDY_ID="STD-van-Berckel-1999" TOTAL_1="13" TOTAL_2="13" WEIGHT="54.56770584824043"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.739880189961315" CI_END="-0.6164145897959132" CI_START="-5.8843265239096665" DF="5.0" EFFECT_SIZE="-3.25037055685279" ESTIMABLE="YES" I2="63.60958079057255" ID="CMP-001.22.02" NO="2" P_CHI2="0.017348990738298764" P_Z="0.01557835734290773" STUDIES="6" TAU2="0.0" TOTAL_1="59" TOTAL_2="61" WEIGHT="99.99999999999999" Z="2.4186468215561114">
<NAME>Glycine or D-serine (any dose) + different antipsychotics</NAME>
<CONT_DATA CI_END="6.898122699063499" CI_START="-7.098122699063502" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="29.4" MEAN_2="29.5" ORDER="9925" SD_1="5.27" SD_2="6.57" SE="3.5705363742720784" STUDY_ID="STD-Diaz-2002" TOTAL_1="5" TOTAL_2="6" WEIGHT="14.166217821832749"/>
<CONT_DATA CI_END="2.8309321253426205" CI_START="-7.7909321253426285" EFFECT_SIZE="-2.480000000000004" ESTIMABLE="YES" MEAN_1="32.29" MEAN_2="34.77" ORDER="9926" SD_1="7.28" SD_2="6.8" SE="2.70970903916326" STUDY_ID="STD-Evins-2000" TOTAL_1="14" TOTAL_2="13" WEIGHT="24.596624925749058"/>
<CONT_DATA CI_END="-12.217137455494054" CI_START="-38.522862544505955" EFFECT_SIZE="-25.370000000000005" ESTIMABLE="YES" MEAN_1="37.33" MEAN_2="62.7" ORDER="9927" SD_1="13.44" SD_2="15.8" SE="6.71076746728718" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="9" TOTAL_2="10" WEIGHT="4.0102962653379155"/>
<CONT_DATA CI_END="8.086885286407835" CI_START="-10.48688528640784" EFFECT_SIZE="-1.2000000000000028" ESTIMABLE="YES" MEAN_1="39.8" MEAN_2="41.0" ORDER="9928" SD_1="7.0" SD_2="10.4" SE="4.738293846040848" STUDY_ID="STD-Javitt-1994" TOTAL_1="7" TOTAL_2="7" WEIGHT="8.044088845266842"/>
<CONT_DATA CI_END="-0.34872933409113216" CI_START="-10.451270665908865" EFFECT_SIZE="-5.399999999999999" ESTIMABLE="YES" MEAN_1="36.4" MEAN_2="41.8" ORDER="9929" SD_1="7.4" SD_2="6.4" SE="2.5772262683154614" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="15" WEIGHT="27.190408998640777"/>
<CONT_DATA CI_END="5.416587917547462" CI_START="-5.8165879175474675" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="44.5" MEAN_2="44.7" ORDER="9930" SD_1="8.4" SD_2="3.4" SE="2.865658737533135" STUDY_ID="STD-Tsai-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="21.992363143172653"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2678072077146663" CI_START="0.4088949777580627" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.10305321648612942" LOG_CI_START="-0.38838822362359243" LOG_EFFECT_SIZE="-0.14266750356873156" METHOD="MH" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.2551324150800801" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="36" WEIGHT="99.99999999999999" Z="1.1379714689771514">
<NAME>Cognitive functions: 1. No clinically significant improvement in cognitive functions</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="18" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>&lt;50% improvement (Glycine, any dose)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9931" O_E="0.0" SE="0.0" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9932" O_E="0.0" SE="0.0" STUDY_ID="STD-Javitt-2001" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2678072077146663" CI_START="0.4088949777580627" DF="0.0" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="0.0" ID="CMP-001.23.02" LOG_CI_END="0.10305321648612942" LOG_CI_START="-0.38838822362359243" LOG_EFFECT_SIZE="-0.14266750356873156" NO="2" P_CHI2="1.0" P_Z="0.2551324150800801" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="18" WEIGHT="99.99999999999999" Z="1.1379714689771514">
<NAME>&lt;20% improvement (Glycine, any dose)</NAME>
<DICH_DATA CI_END="1.2678072077146663" CI_START="0.4088949777580627" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.10305321648612942" LOG_CI_START="-0.38838822362359243" LOG_EFFECT_SIZE="-0.14266750356873156" ORDER="9933" O_E="0.0" SE="0.28867513459481287" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="0.08333333333333333" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9934" O_E="0.0" SE="0.0" STUDY_ID="STD-Javitt-2001" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.758335570568576" CI_END="0.5962508733526861" CI_START="-6.170707653453462" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.7872283900503882" ESTIMABLE="YES" I2="74.48618486863839" I2_Q="0.0" ID="CMP-001.24" NO="24" P_CHI2="0.0082585925413593" P_Q="1.0" P_Z="0.10640364494315979" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="8.682287902312138" TOTALS="SUB" TOTAL_1="39" TOTAL_2="41" UNITS="" WEIGHT="100.00000000000001" Z="1.614570930070313">
<NAME>Cognitive functions: 2. Average endpoint score (PANSS-cognitive, high score = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.758335570568576" CI_END="0.5962508733526861" CI_START="-6.170707653453462" DF="3.0" EFFECT_SIZE="-2.7872283900503882" ESTIMABLE="YES" I2="74.48618486863839" ID="CMP-001.24.01" NO="1" P_CHI2="0.0082585925413593" P_Z="0.10640364494315979" STUDIES="4" TAU2="8.682287902312138" TOTAL_1="39" TOTAL_2="41" WEIGHT="100.00000000000001" Z="1.614570930070313">
<NAME>Glycine or D-serine (any dose) + different antipsychotics - heterogeneous data - random effects model</NAME>
<CONT_DATA CI_END="-4.385921129463782" CI_START="-14.254078870536222" EFFECT_SIZE="-9.320000000000002" ESTIMABLE="YES" MEAN_1="13.78" MEAN_2="23.1" ORDER="9935" SD_1="3.7" SD_2="6.94" SE="2.517433437275177" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="9" TOTAL_2="10" WEIGHT="19.84119802467564"/>
<CONT_DATA CI_END="0.6717338038915504" CI_START="-6.011733803891554" EFFECT_SIZE="-2.6700000000000017" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="21.67" ORDER="9936" SD_1="2.1" SD_2="3.61" SE="1.7049975562054822" STUDY_ID="STD-Javitt-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="25.714227380469715"/>
<CONT_DATA CI_END="2.905246429099366" CI_START="-2.3052464290993644" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="12.6" ORDER="9937" SD_1="4.4" SD_2="2.4" SE="1.3292317867313974" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="15" WEIGHT="28.520037915064623"/>
<CONT_DATA CI_END="1.9872516883580076" CI_START="-4.587251688358009" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="19.3" ORDER="9938" SD_1="3.8" SD_2="3.7" SE="1.6772000476985445" STUDY_ID="STD-Tsai-1999" TOTAL_1="10" TOTAL_2="10" WEIGHT="25.924536679790023"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0024643314856181682" CI_END="15.252956990785027" CI_START="0.23616726022808154" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8979591836734695" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="1.1833540456692144" LOG_CI_START="-0.6267803086183714" LOG_EFFECT_SIZE="0.27828686852542145" METHOD="MH" NO="25" P_CHI2="0.9604076660739644" P_Q="0.0" P_Z="0.546746328406484" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="7" WEIGHT="200.0" Z="0.6026428241509454">
<NAME>Adverse effects: 1. Ampakine CX516 (any dose) + clozapine</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="31.51606118730591" CI_START="0.10280472489071739" DF="0.0" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="1.4985319349752662" LOG_CI_START="-0.987986924768654" LOG_EFFECT_SIZE="0.25527250510330607" NO="1" P_CHI2="1.0" P_Z="0.6873675820687757" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="2" WEIGHT="100.0" Z="0.4024300192095259">
<NAME>hypertension</NAME>
<DICH_DATA CI_END="31.51606118730591" CI_START="0.10280472489071739" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4985319349752662" LOG_CI_START="-0.987986924768654" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="9939" O_E="0.0" SE="1.4605934866804429" STUDY_ID="STD-Goff-1999c" TOTAL_1="4" TOTAL_2="2" VAR="2.133333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="41.366590273818105" CI_START="0.09669639130329037" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="1.6166497247559435" LOG_CI_START="-1.014589733427981" LOG_EFFECT_SIZE="0.3010299956639812" NO="2" P_CHI2="1.0" P_Z="0.6538184379997736" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="100.00000000000001" Z="0.44846389630754013">
<NAME>suicidal ideas</NAME>
<DICH_DATA CI_END="41.366590273818105" CI_START="0.09669639130329037" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6166497247559435" LOG_CI_START="-1.014589733427981" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="9940" O_E="0.0" SE="1.5456030825826172" STUDY_ID="STD-Goff-2001a" TOTAL_1="8" TOTAL_2="5" VAR="2.388888888888889" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="73.014034432097" CI_START="0.13374997116591358" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="1.863406346292985" LOG_CI_START="-0.8737063029327973" LOG_EFFECT_SIZE="0.49485002168009407" METHOD="MH" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.4785141381784974" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="0.7086944123517833">
<NAME>Adverse effects: 2. D-cycloserine (any dose) + different antipsychotics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.014034432097" CI_START="0.13374997116591358" DF="0.0" EFFECT_SIZE="3.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.26.01" LOG_CI_END="1.863406346292985" LOG_CI_START="-0.8737063029327973" LOG_EFFECT_SIZE="0.49485002168009407" NO="1" P_CHI2="1.0" P_Z="0.4785141381784974" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="0.7086944123517833">
<NAME>vague somatic discomfort</NAME>
<DICH_DATA CI_END="73.014034432097" CI_START="0.13374997116591358" EFFECT_SIZE="3.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.863406346292985" LOG_CI_START="-0.8737063029327973" LOG_EFFECT_SIZE="0.49485002168009407" ORDER="9941" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Goff-1999a" TOTAL_1="23" TOTAL_2="24" VAR="2.585" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.14851801825381" CI_END="1.6923526295603601" CI_START="0.35786531076195416" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7782250957765553" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.22849086054458997" LOG_CI_START="-0.4462803973764432" LOG_EFFECT_SIZE="-0.10889476841592657" METHOD="MH" NO="27" P_CHI2="0.7899888505787303" P_Q="0.0" P_Z="0.5269955193801985" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="87" TOTAL_2="104" WEIGHT="600.0" Z="0.6325990376579528">
<NAME>Adverse effects: 3. Glycine or D-serine (any dose) + different antipsychotics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.01873304142796" CI_START="0.06124585464121784" DF="0.0" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="0.7795050807885044" LOG_CI_START="-1.212923300716395" LOG_EFFECT_SIZE="-0.21670910996394532" NO="1" P_CHI2="1.0" P_Z="0.6698483470506862" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="0.42635615372056834">
<NAME>constipation</NAME>
<DICH_DATA CI_END="6.01873304142796" CI_START="0.06124585464121784" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7795050807885044" LOG_CI_START="-1.212923300716395" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="9942" O_E="0.0" SE="1.1703622939755296" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="17" VAR="1.3697478991596639" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.01873304142796" CI_START="0.06124585464121784" DF="0.0" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.27.02" LOG_CI_END="0.7795050807885044" LOG_CI_START="-1.212923300716395" LOG_EFFECT_SIZE="-0.21670910996394532" NO="2" P_CHI2="1.0" P_Z="0.6698483470506862" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="0.42635615372056834">
<NAME>diarrhoea</NAME>
<DICH_DATA CI_END="6.01873304142796" CI_START="0.06124585464121784" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7795050807885044" LOG_CI_START="-1.212923300716395" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="9943" O_E="0.0" SE="1.1703622939755296" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="17" VAR="1.3697478991596639" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0626665488742106" CI_START="0.009595479832057888" DF="0.0" EFFECT_SIZE="0.17142857142857143" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.27.03" LOG_CI_END="0.48609971510003436" LOG_CI_START="-2.017933303033298" LOG_EFFECT_SIZE="-0.765916793966632" NO="3" P_CHI2="1.0" P_Z="0.23052749005088446" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="1.19900122758609">
<NAME>dyspepsia</NAME>
<DICH_DATA CI_END="3.0626665488742093" CI_START="0.009595479832057888" EFFECT_SIZE="0.17142857142857143" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.48609971510003414" LOG_CI_START="-2.017933303033298" LOG_EFFECT_SIZE="-0.765916793966632" ORDER="9944" O_E="0.0" SE="1.4708813900148656" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="17" VAR="2.1634920634920634" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8404776578947777" CI_START="0.12977481021723533" DF="0.0" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.27.04" LOG_CI_END="0.45339137763328363" LOG_CI_START="-0.8868095975611742" LOG_EFFECT_SIZE="-0.21670910996394532" NO="4" P_CHI2="1.0" P_Z="0.5261798362651673" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="17" WEIGHT="100.0" Z="0.6338482936701858">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="2.8404776578947777" CI_START="0.12977481021723533" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.45339137763328363" LOG_CI_START="-0.8868095975611742" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="9945" O_E="0.0" SE="0.7872406869310452" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="17" VAR="0.6197478991596639" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3449592220050444" CI_END="7.828924428956923" CI_START="0.363111961991" DF="1.0" EFFECT_SIZE="1.686053412462908" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.27.05" LOG_CI_END="0.8937021009270967" LOG_CI_START="-0.4399594438959397" LOG_EFFECT_SIZE="0.22687132851557845" NO="5" P_CHI2="0.5569807474055328" P_Z="0.5048837315196356" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="29" WEIGHT="100.0" Z="0.666825304727956">
<NAME>nausea</NAME>
<DICH_DATA CI_END="78.56443206881275" CI_START="0.1599992210581286" EFFECT_SIZE="3.5454545454545454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8952259753992482" LOG_CI_START="-0.7958821316626998" LOG_EFFECT_SIZE="0.5496719218682742" ORDER="9946" O_E="0.0" SE="1.5807702232881597" STUDY_ID="STD-Heresco_x002d_Levy-1999" TOTAL_1="10" TOTAL_2="12" VAR="2.4988344988344986" WEIGHT="20.237388724035608"/>
<DICH_DATA CI_END="7.553596645195484" CI_START="0.19520367120161577" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8781537902025403" LOG_CI_START="-0.7095120188024684" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="9947" O_E="0.0" SE="0.9326027552820461" STUDY_ID="STD-Tsai-1998" TOTAL_1="14" TOTAL_2="17" VAR="0.8697478991596639" WEIGHT="79.76261127596439"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="63.149196457537265" CI_START="0.1425196281959308" DF="0.0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.27.06" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" NO="6" P_CHI2="1.0" P_Z="0.4797519380309755" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0" Z="0.706701603364751">
<NAME>weakness - lower-extremity</NAME>
<DICH_DATA CI_END="63.149196457537265" CI_START="0.1425196281959308" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8003678287428493" LOG_CI_START="-0.8461253193035243" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="9948" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Javitt-1994" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>